LivaNova (LIVN) 10-Q 3 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Jul. 27, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-37599
Entity Registrant Name	LivaNova PLC
Entity Incorporation, State or Country Code	X0
Entity Tax Identification Number	98-1268150
Entity Address, Address Line One	20 Eastbourne Terrace
Entity Address, City or Town	London
Entity Address, Country	GB
Entity Address, Postal Zip Code	W2 6LG
Country Region	44
City Area Code	0
Local Phone Number	203 325-0660
Title of 12(b) Security	Ordinary Shares - £1.00 par value per share
Trading Symbol	LIVN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		53,545,733
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001639691

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	[1]	Jun. 30, 2022	Jun. 30, 2021	[1]
Income Statement [Abstract]
Net sales	$ 254,151	$ 264,483		$ 494,326	$ 512,086
Cost of sales	69,801	92,204		141,533	176,399
Gross profit	184,350	172,279		352,793	335,687
Operating expenses:
Selling, general and administrative	116,482	122,748		235,007	238,429
Research and development	34,229	52,557		75,147	97,182
Other operating expenses	1,883	33,236		1,378	42,036
Operating income (loss)	31,756	(36,262)		41,261	(41,960)
Interest expense	(14,388)	(16,515)		(22,228)	(32,451)
Foreign exchange and other income/(expense)	1,633	239		5,537	(6,204)
Income (loss) before tax	19,001	(52,538)		24,570	(80,615)
Income tax expense	2,515	3,908		5,052	6,552
Losses from equity method investments	(42)	(41)		(81)	(81)
Net income (loss)	$ 16,444	$ (56,487)	[2]	$ 19,437	$ (87,248)	[2],[3]
Basic loss per share (in dollars per share)	$ 0.31	$ (1.15)		$ 0.36	$ (1.79)
Diluted loss per share (in dollars per share)	$ 0.30	$ (1.15)		$ 0.36	$ (1.79)
Shares used in computing basic loss per share (in shares)	53,506	48,928		53,420	48,833
Shares used in computing diluted loss per share (in shares)	54,080	48,928		54,144	48,833
[1]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[2]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[3]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	[1]	Jun. 30, 2022	Jun. 30, 2021	[1]
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 16,444	$ (56,487)	[2]	$ 19,437	$ (87,248)	[2],[3]
Other comprehensive (loss) income:
Net change in unrealized loss on derivatives	(1,232)	(1,250)		(1,927)	(1,585)
Tax effect	0	42		0	381
Net of tax	(1,232)	(1,208)		(1,927)	(1,204)
Foreign currency translation adjustment	(37,506)	22,345		(45,766)	(3,530)
Total other comprehensive (loss) income	(38,738)	21,137		(47,693)	(4,734)
Total comprehensive loss	$ (22,294)	$ (35,350)		$ (28,256)	$ (91,982)
[1]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[2]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[3]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 109,022	$ 207,992
Restricted cash	297,747	0
Accounts receivable, net of allowance of $13,109 at June 30, 2022 and $13,512 at December 31, 2021	176,949	185,354
Inventories	119,415	105,840
Prepaid and refundable taxes	30,917	37,621
Current derivative assets	2,520	106,629
Prepaid expenses and other current assets	35,357	35,745
Total Current Assets	771,927	679,181
Property, plant and equipment, net	143,312	150,066
Goodwill	898,070	899,525
Intangible assets, net	389,379	399,682
Operating lease assets	38,419	40,600
Investments	13,965	16,598
Deferred tax assets	2,422	2,197
Long-term derivative assets	61,608	0
Other assets	17,143	13,102
Total Assets	2,336,245	2,200,951
Current Liabilities:
Current debt obligations	6,240	229,673
Accounts payable	74,346	68,000
Accrued liabilities and other	83,952	88,937
Current derivative liabilities	3,232	183,109
Current litigation provision liability	30,960	32,845
Taxes payable	14,891	15,140
Accrued employee compensation and related benefits	50,272	79,266
Total Current Liabilities	263,893	696,970
Long-term debt obligations	459,792	9,849
Contingent consideration	91,840	86,830
Deferred tax liabilities	7,661	7,728
Long-term operating lease liabilities	31,857	35,919
Long-term employee compensation and related benefits	17,917	19,105
Long-term derivative liabilities	134,090	0
Other long-term liabilities	47,192	49,905
Total Liabilities	1,054,242	906,306
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Ordinary Shares, £1.00 par value: unlimited shares authorized; 53,810,418 shares issued and 53,506,408 shares outstanding at June 30, 2022; 53,761,510 shares issued and 53,263,297 shares outstanding at December 31, 2021	82,359	82,295
Additional paid-in capital	2,133,258	2,117,961
Accumulated other comprehensive loss	(54,870)	(7,177)
Accumulated deficit	(878,347)	(897,784)
Treasury stock at cost, 304,010 ordinary shares at June 30, 2022; 498,213 ordinary shares at December 31, 2021	(397)	(650)
Total Stockholders’ Equity	1,282,003	1,294,645
Total Liabilities and Stockholders’ Equity	$ 2,336,245	$ 2,200,951

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) $ in Thousands	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 £ / shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 £ / shares
Statement of Financial Position [Abstract]
Allowance for doubtful accounts | $	$ 13,109		$ 13,512
Ordinary shares, par value (in pounds per share) | £ / shares		£ 1		£ 1
Ordinary shares issued (in shares)	53,810,418		53,761,510
Ordinary shares outstanding (in shares)	53,506,408		53,263,297
Treasury stock (in shares)	304,010		498,213

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Activities:
Net income (loss)	$ 19,437	$ (87,248)	[1],[2],[3]
Non-cash items included in net income (loss):
Remeasurement of contingent consideration to fair value	(27,359)	10,746	[1]
Stock-based compensation	21,765	19,452	[1]
Amortization	12,917	13,353	[1]
Amortization of debt issuance costs	11,721	8,989	[1]
Depreciation	11,096	12,256	[1]
Remeasurement of derivative instruments	(5,098)	13,191	[1]
Amortization of operating lease assets	4,939	8,947	[1]
Remeasurement of Respicardia investment and loan	0	(4,640)	[1]
Deferred tax expense	645	913	[1]
Other	1,342	1,356	[1]
Changes in operating assets and liabilities:
Accounts receivable, net	(875)	(4,664)	[1]
Inventories	(16,461)	3,897	[1]
Other current and non-current assets	2,846	18,786	[1]
Accounts payable and accrued current and non-current liabilities	(19,387)	3,558	[1]
Taxes payable	116	2,491	[1]
Litigation provision liability	(2,064)	23,728	[1]
Net cash provided by operating activities	15,580	45,111	[1]
Investing Activities:
Purchases of property, plant and equipment	(11,342)	(14,622)	[1]
Acquisition, net of cash acquired	(8,857)	0
Purchase of investments	(781)	(2,097)	[1]
Proceeds from sale of Heart Valves, net of cash disposed	0	41,759	[1]
Proceeds from sale of Respicardia investment and loan	0	23,057	[1]
Other	(650)	(1,382)	[1]
Net cash (used in) provided by investing activities	(21,630)	46,715	[1]
Financing Activities:
Proceeds from long-term debt obligations	218,342	0	[1]
Shares repurchased from employees for minimum tax withholding	(8,223)	(11,072)	[1]
Payment of debt issuance costs	(2,861)	(376)	[1]
Proceeds from share issuances under ESPP	1,788	1,750	[1]
Payment of contingent consideration	0	(4,387)	[1]
Repayment of long-term debt obligations	(784)	(1,287)	[1]
Other	295	1,285	[1]
Net cash provided by (used in) financing activities	208,557	(14,087)	[1]
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(3,730)	(1,185)	[1]
Net increase in cash, cash equivalents and restricted cash	198,777	76,554	[1]
Cash, cash equivalents and restricted cash at beginning of period	207,992	252,832	[1]
Cash, cash equivalents and restricted cash at end of period	$ 406,769	$ 329,386	[1]
[1]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[2]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[3]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Financial Statements	Note 1. Unaudited Condensed Consolidated Financial Statements Basis of Presentation The accompanying condensed consolidated financial statements of LivaNova as of, and for the three and six months ended June 30, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova at December 31, 2021 has been derived from audited financial statements contained in our 2021 Form 10-K, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries, for the three and six months ended June 30, 2022, and are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying our 2021 Form 10-K. Global Developments COVID-19 The COVID-19 pandemic (“COVID-19”) and its effects on the economy, employment, patient behaviors and supply chain, among others, has caused and may continue to cause variable demand for our products. Throughout the pandemic, healthcare customers have diverted medical resources and priorities towards the treatment of COVID-19, and public health bodies have delayed elective procedures, which has negatively impacted the usage of our products. Further, some people have avoided seeking treatment for non-COVID-19 procedures, and hospitals and clinics have experienced staffing shortages, which has negatively impacted the demand for our products. While the recovery of global cardiopulmonary procedures has resulted in stronger demand for our Cardiopulmonary products, our Neuromodulation business continues to experience ongoing COVID-19 related headwinds as described above. Our Advanced Circulatory Support (“ACS”) business has been similarly negatively impacted by a reduction in patients treated with extracorporeal membrane oxygenation (“ECMO”) related to fewer severe COVID-19 cases and hospital staffing challenges. We are monitoring the potential for various strains of the virus to cause a resumption of high levels of infection and hospitalization that, in turn, may affect the demand for our products. Moreover, although our RECOVER study and ANTHEM-HFrEF and OSPREY clinical trials continue to progress, there may be delays or closures of sites in the future should COVID-19 or variants thereof strengthen or reemerge. Our net sales and profitability have been negatively affected by the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies. Furthermore, we continue to experience supply chain delays and interruptions, labor shortages, inflationary pressures and logistical issues in the wake of COVID-19. Though, to date, our supply of raw materials and the production and distribution of finished products have not been materially affected, demand and low capacity worldwide have caused longer lead times and put price pressure on key raw materials. Moreover, freight and labor costs at our manufacturing facilities have increased substantially due to COVID-related disruptions and in the wake of inflation globally. The Company continues to respond to such challenges, and while we have business continuity plans in place, the impact of the ongoing challenges we are experiencing, along with their potential escalation, may adversely affect our business and the recoverability of our tangible and intangible assets. The future impact of pandemic-related developments remains uncertain. Ukraine Invasion In February 2022, Russia launched an invasion in Ukraine which caused us to assess our ability to sell in the market due to international sanctions, to consider the potential impact of raw material sourced from the region, and to determine whether we are able to transact in a compliant fashion. Although the region represented 1% of our total net sales for 2021, the Russian invasion of Ukraine has increased economic uncertainties, and a significant escalation or continuation of the conflict could have a material, global impact on our operating results. In addition, our Russian employees and local subsidiary are subject to evolving laws and regulations imposed by the Russian authorities in response to international sanctions. Revision of Previously Issued Financial Statements During the fourth quarter of 2021, the Company identified and corrected an error related to foreign currency exchange rates utilized to calculate inventory and cost of sales for the years ended December 31, 2017 through 2020 and the nine months ended September 30, 2021. Using the guidance in ASC Topic 250, Accounting Changes and Error Corrections , ASC Topic 250-S99-1, Assessing Materiality , and ASC Topic 250-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements , we evaluated whether our previously issued consolidated financial statements were materially misstated due to these errors. Based upon our evaluation of both quantitative and qualitative factors, we believe that the effects of these errors were not material individually or in the aggregate to any previously reported quarterly or annual period. Accordingly, we have revised our previously issued financial statements as shown below (in thousands): Consolidated Statements of Income (Loss) Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Cost of sales $ 90,803 $ 1,401 $ 92,204 $ 173,723 $ 2,676 $ 176,399 Operating loss (34,861) (1,401) (36,262) (39,284) (2,676) (41,960) Loss before tax (51,137) (1,401) (52,538) (77,939) (2,676) (80,615) Income tax expense 4,140 (232) 3,908 6,996 (444) 6,552 Net loss (55,318) (1,169) (56,487) (85,016) (2,232) (87,248) Basic and diluted loss per share $ (1.13) $ (0.02) $ (1.15) $ (1.74) $ (0.05) $ (1.79) Consolidated Statements of Comprehensive Income (Loss) Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Net loss $ (55,318) $ (1,169) $ (56,487) $ (85,016) $ (2,232) $ (87,248) Total comprehensive loss (34,181) (1,169) (35,350) (89,750) (2,232) (91,982) Consolidated Statements of Stockholders’ Equity As Previously Reported Adjustments As Revised Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity June 30, 2021 $ (837,418) $ 1,040,470 $ (11,796) $ (11,796) $ (849,214) $ 1,028,674 Consolidated Statements of Cash Flows Six Months Ended June 30, 2021 As Previously Reported Adjustments As Revised Net loss $ (85,016) $ (2,232) $ (87,248) Deferred tax expense (benefit) 1,357 (444) 913 Changes in operating assets and liabilities: Inventories 1,221 2,676 3,897 Net cash used in operating activities 45,111 — 45,111 Reclassifications We have reclassified certain prior period amounts on the condensed consolidated statements of income (loss), the condensed consolidated balance sheets and the condensed consolidated statements of cash flows for comparative purposes. These reclassifications did not have a material effect on our financial condition, results of operations or cash flows. Significant Accounting Policies Our significant accounting policies are detailed below and in “Note 2. Basis of Presentation, Use of Accounting Estimates and Significant Accounting Policies” and “Note 3. Revenue Recognition” of our 2021 Form 10-K. Restricted Cash The Company classifies cash that is not available for use in its operations as restricted cash within current assets on the condensed consolidated balance sheet. As of June 30, 2022, our restricted cash balance totaled $297.7 million and was comprised of cash deposits with Barclays held as collateral for a first demand bank guarantee of €270.0 million (approximately $281.2 million as of June 30, 2022) to obtain the suspension of the Court of Appeal of Milan judgment for the payment of damages in connection with the SNIA litigation until review of such judgment by the Italian Supreme Court (the “SNIA Litigation Guarantee”). As security for the SNIA Litigation Guarantee, LivaNova is required to grant cash collateral to Barclays in US dollars in an amount equal to the USD equivalent of 105% of the amount of the SNIA Litigation Guarantee calibrated on a biweekly basis. For additional information regarding the SNIA litigation, please refer to “Note 8. Commitments and Contingencies.”

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Note 2. Business Combinations As of December 31, 2021, LivaNova owned a 3% investment in ALung Technologies, Inc. (“ALung”), a privately held medical device company focused on creating advanced medical devices for treating respiratory failure. On May 2, 2022, we acquired the remaining 97% of equity interests in ALung for a purchase price of up to $110.0 million, consisting of $10.0 million paid at closing, subject to customary adjustments, and contingent consideration of up to $100.0 million payable upon achievement of certain sales-based milestones beginning in 2023 and ending in 2027. The following table presents the acquisition date fair value of the consideration transferred and the fair value of our interest in ALung prior to the acquisition (in thousands): Cash and other considerations $ 15,586 Contingent consideration 26,369 Fair value of consideration transferred $ 41,955 The following table presents the preliminary purchase price allocation at fair value for the ALung acquisition (in thousands): Purchase Price Allocation Developed technology - 15-year life $ 13,950 Goodwill 25,893 Other assets and liabilities, net 2,112 Net assets acquired $ 41,955 Goodwill arising from the ALung acquisition, which is not deductible for tax purposes, primarily represents the synergies anticipated between ALung and our ACS business. The assets acquired, including goodwill, are recognized in our ACS segment. We recognized ALung acquisition-related expenses of approximately $4.4 million during the three and six months ended June 30, 2022 within “Selling, general and administrative” expenses on our consolidated statement of income (loss). The Company’s consolidated financial statements include the operating results of ALung from the acquisition date. Separate post-acquisition operating results and pro forma financial information for this acquisition have not been presented as the effect was not material for disclosure purposes. The contingent consideration payments are triggered upon the achievement of thresholds associated with sales of products covered by the purchase agreement and are estimated to occur during the years reflected in the table below. The sales-based earnout was valued using projected sales from our internal strategic plan and is a Level 3 fair value measurement, which includes the following significant unobservable inputs (in thousands): ALung Acquisition Fair value at May 2, 2022 Valuation Technique Unobservable Input Ranges Sales-based earnout $ 26,369 Monte Carlo simulation Risk-adjusted discount rate 9.7% - 11.1% Credit risk discount rate 6.4% - 8.0% Revenue volatility 38.5% Projected years of earnout 2023 - 2027 For a reconciliation of the beginning and ending balance of contingent consideration liabilities refer to “Note 5. Fair Value Measurements.”

Divestiture of Heart Valve Busi

Divestiture of Heart Valve Business	6 Months Ended
	Jun. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Divestiture of Heart Valve Business	Note 3. Divestiture of Heart Valve Business On December 2, 2020, LivaNova entered into a Purchase Agreement with Mitral Holdco S.à r.l. (“Mitral”), a company incorporated under the laws of Luxembourg and wholly-owned and controlled by funds advised by Gyrus Capital S.A., a Swiss private equity firm. The Purchase Agreement provides for the divestiture of certain of LivaNova’s subsidiaries as well as certain other assets and liabilities relating to the Company’s Heart Valve business and site management operations conducted by the Company’s subsidiary LivaNova Site Management (“LSM”) at the Company’s Saluggia campus for €60.0 million. On April 9, 2021, LivaNova and the Purchaser entered into an A&R Purchase Agreement which amends and restates the original Purchase Agreement to, among other things, defer the closing of the sale and purchase of LSM by up to two years and include or amend certain additional terms relating to such deferral, including certain amendments relating to the potential hazardous substances liabilities of LSM and the related expense reimbursement provisions. The closing of the sale of the Heart Valve business occurred on June 1, 2021, and we received €34.8 million (approximately $42.5 million as of June 1, 2021), subject to customary trade working capital and net indebtedness adjustments, as set forth in the Purchase Agreement. We also received $3.0 million in December 2021 and the remaining deferred purchase price of €9.3 million in July 2022. In July 2022, we also made a €4.8 million payment to Mitral upon finalizing the trade working capital and net indebtedness adjustments. During the three and six months ended June 30, 2021, we recognized a (loss) gain from the sale of the Heart Valve business of $(0.1) million and $0.8 million, respectively, which is included within other operating expenses on the condensed consolidated statements of income (loss). On July 29, 2022, we received a demand letter from Mitral for approximately €20.8 million ($21.2 million as of July 29, 2022) for breach of warranty claims under the A&R Purchase Agreement. Specifically, the claims allege failure to disclose certain information relating to a supplier, thereby allegedly impacting the profitability of Mitral’s business in China and Japan. We are currently assessing the merits of Mitral’s claims including whether Mitral has suffered a recoverable loss under the A&R Purchase Agreement, pursuant to which warranty claims of this type, subject to certain exceptions, are capped at €8 million, and the amount of any such loss. The Company has not recognized a liability related to this matter because any potential loss is not currently probable.

Investments

Investments	6 Months Ended
	Jun. 30, 2022
Investments [Abstract]
Investments	Note 4. Investments Investments on the condensed consolidated balance sheets represent the carrying value of our investments in equity securities of non-consolidated affiliates without readily determinable fair values for which we do not exert significant influence over the investee. These equity investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. As of June 30, 2022 and December 31, 2021, the carrying value of our investments was $14.0 million and $16.6 million, respectively. As of December 31, 2021, LivaNova owned a 3% investment in ALung with a carrying value of $3.0 million, as well as held a note receivable due from ALung with a carrying value of $2.5 million. On May 2, 2022, we acquired the remaining 97% of equity interests in ALung. Please refer to “Note 2. Business Combinations” for further details. In April 2021, Zoll Medical Corporation acquired Respicardia Inc., a privately funded U.S. company in which we had an equity investment and also to which we had a loan outstanding. As a result of the acquisition, we received proceeds of $23.1 million for both our investment and loan receivable, which had carrying values of $17.7 million and $0.8 million as of December 31, 2020, respectively. The Company recorded a gain of $4.6 million during the first quarter of 2021 to adjust the investment and loans receivable to fair value, which is included in “Foreign exchange and other income/(expense)” on the condensed consolidated statement of income (loss). During the second quarter of 2021, the Company received a cash dividend from its investment in MD Start II of $3.1 million, which is included in “Foreign exchange and other income/(expense)” on the condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 5. Fair Value Measurements We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers between Level 1, Level 2, or Level 3 during the six months ended June 30, 2022 and 2021. Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands): Fair Value as of June 30, 2022 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - designated as cash flow hedges (foreign currency exchange rate “FX”) $ 585 $ — $ 585 $ — Derivative assets - freestanding instruments (FX) 2,092 — 2,092 — Derivative assets - capped call derivatives 61,608 — — 61,608 Convertible notes receivable 278 — — 278 $ 64,563 $ — $ 2,677 $ 61,886 Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 3,386 $ — $ 3,386 $ — Derivative liabilities - freestanding instruments (FX) 3 — 3 — Derivative liabilities - embedded exchange feature 134,090 — — 134,090 Contingent consideration arrangements 97,392 — — 97,392 $ 234,871 $ — $ 3,389 $ 231,482 Fair Value as of December 31, 2021 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - designated as cash flow hedges (foreign currency exchange rate “ FX ” ) $ 243 $ — $ 243 $ — Derivative assets - freestanding instruments (FX) 61 — 61 — Derivative assets - capped call derivatives 106,629 — — 106,629 Convertible notes receivable 2,767 — — 2,767 $ 109,700 $ — $ 304 $ 109,396 Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 1,286 $ — $ 1,286 $ — Derivative liabilities - freestanding instruments (FX) 427 — 427 — Derivative liabilities - embedded exchange feature 181,700 — — 181,700 Contingent consideration arrangements 98,382 — — 98,382 $ 281,795 $ — $ 1,713 $ 280,082 The following table provides a reconciliation of the beginning and ending balances of our recurring fair value measurements, using significant unobservable inputs (Level 3) (in thousands): Capped Call Derivative Asset Convertible Notes Receivable Embedded Exchange Feature Derivative Liability Contingent Consideration Liability Arrangements As of December 31, 2021 $ 106,629 $ 2,767 $ 181,700 $ 98,382 Additions — — — 26,369 Utilized as business combination consideration — (2,489) — — Changes in fair value (1) (45,021) — (47,610) (27,359) Total at June 30, 2022 61,608 278 134,090 97,392 Less current portion at June 30, 2022 — — — 5,552 Long-term portion at June 30, 2022 $ 61,608 $ 278 $ 134,090 $ 91,840 (1) The decrease in fair value associated with contingent consideration arrangements during the six months ended June 30, 2022 was primarily related to the change in discount rates due to increasing interest rates and the change in probability of the regulatory milestone-based payment associated with the acquisition of TandemLife. Embedded Exchange Feature and Capped Call Derivatives In June 2020, the Company issued $287.5 million in cash exchangeable senior notes and entered into related capped call transactions. The cash exchangeable senior notes include an embedded exchange feature that is bifurcated from the cash exchangeable senior notes. Please refer to “Note 6. Financing Arrangements” for further details. The embedded exchange feature derivative is measured at fair value using a binomial lattice model and discounted cash flows that utilize observable and unobservable market data. The capped call derivative is measured at fair value using the Black-Scholes model utilizing observable and unobservable market data, including stock price, remaining contractual term, expected volatility, risk-free interest rate and expected dividend yield, as applicable. The embedded exchange feature and capped call derivatives are classified as Level 3 as the Company uses historical volatility and implied volatility from options traded to determine expected stock price volatility, an unobservable input that is significant to the valuation. In general, an increase in our stock price or stock price volatility would increase the fair value of the embedded exchange feature and capped call derivatives which would result in an increase in expense. As time to the expiration of the derivatives decreases, the fair value of the derivatives would decrease. The future impact on net income depends on how significant inputs such as stock price, stock price volatility and time to the expiration of the derivatives change in relation to other inputs. Changes in the fair value of the embedded exchange feature derivative and capped call derivatives are recognized in “Foreign exchange and other income/(expense)” in the condensed consolidated statements of income (loss). The fair value of the embedded exchange feature derivative liability and the capped call derivative assets were $134.1 million and $61.6 million, respectively, as of June 30, 2022 and the stock price volatility was 54%. As of June 30, 2022, a 10% lower volatility, holding other inputs constant, would result in approximate fair value for the embedded exchange feature derivative of $118.5 million and a 10% higher volatility, holding other inputs constant, would result in approximate fair value of $146.8 million. As of June 30, 2022, a 10% lower volatility, holding other inputs constant, would result in approximate fair value for the capped call derivatives of $65.0 million and a 10% higher volatility, holding other inputs constant, would result in approximate fair value of $57.4 million. Contingent Consideration Arrangements The following table provides the fair value of our Level 3 contingent consideration arrangements by acquisition (in thousands): June 30, 2022 December 31, 2021 ImThera $ 70,283 $ 86,830 ALung 21,557 — TandemLife 5,552 11,552 $ 97,392 $ 98,382 The ImThera business combination involved contingent consideration arrangements composed of potential cash payments upon the achievement of a certain regulatory milestone and a sales-based earnout associated with sales of products. The sales-based earnouts are valued using projected sales from our internal strategic plan. These arrangements are Level 3 fair value measurements and include the following significant unobservable inputs as of June 30, 2022: ImThera Acquisition Valuation Technique Unobservable Input Inputs Regulatory milestone-based payment Discounted cash flow Discount rate 11.8% Probability of payment 85% Projected payment year 2024 Sales-based earnout Monte Carlo simulation Risk-adjusted discount rate 14.4% Credit risk discount rate 12.4% - 13.4% Revenue volatility 32.5% Probability of payment 85% Projected years of earnout 2025 - 2028 The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of June 30, 2022: TandemLife Acquisition Valuation Technique Unobservable Input Inputs Regulatory milestone-based payment Discounted cash flow Discount rate 10.1% Probability of payment 45% Projected payment year 2023 The ALung business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain sales-based thresholds associated with sales of products. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of June 30, 2022: ALung Acquisition Valuation Technique Unobservable Input Inputs Sales-based earnout Monte Carlo simulation Risk-adjusted discount rate 10.4% - 11.2% Credit risk discount rate 11.0% - 13.2% Revenue volatility 37.5% Projected years of earnout 2023 - 2027

Financing Arrangements

Financing Arrangements	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Financing Arrangements	Note 6. Financing Arrangements The outstanding principal amount of our long-term debt as of June 30, 2022 and December 31, 2021 was as follows (in thousands, except interest rates): June 30, 2022 December 31, 2021 Maturity Interest Rate 2020 Cash Exchangeable Senior Notes $ 232,081 $ 225,140 December 2025 3.00% Bridge Loan Facility 220,000 — N/A 5.83% Bank of America Merrill Lynch Banco Múltiplo S.A. 6,499 6,113 July 2023 11.46% Mediocredito Italiano 2,332 3,379 December 2023 0.50% - 2.74% Bank of America, U.S. 1,500 1,500 January 2023 5.45% Other 585 663 Total long-term facilities 462,997 236,795 Less current portion of long-term debt 3,205 226,946 Total long-term debt $ 459,792 $ 9,849 Revolving Credit The outstanding principal amount of our short-term unsecured revolving credit agreements and other agreements with various banks was $3.0 million and $2.7 million at June 30, 2022 and December 31, 2021, respectively, with interest rates ranging from 3.14% to 11.63% and loan terms ranging from overnight to 364 days, as of June 30, 2022. On August 13, 2021, LivaNova PLC and its wholly-owned subsidiary, LivaNova USA, Inc. (the “Borrower”) entered into a First Lien Credit Agreement with the lenders and issuing banks party thereto and Goldman Sachs Bank USA, as First Lien Administrative Agent and First Lien Collateral Agent, relating to a $125 million senior secured multi-currency revolving credit facility to be made available to the Borrower (the “2021 First Lien Credit Agreement”). The 2021 First Lien Credit Agreement, as amended from time to time, expires on August 13, 2026 and bears interest at a rate equal to, for U.S. dollar-denominated loans, an adjusted Secured Overnight Financing Rate (“SOFR”) with a floor of 0.00%, or a Base Rate, plus, in each case, a variable margin based on the Company’s senior secured net leverage ratio. Interest is paid monthly or quarterly, as selected by the Borrower, with any outstanding principal due at maturity. The First Lien Credit Agreement also contemplates the payment of commitment fees on the unused portion of the commitments, at a variable percentage based on the Company’s senior secured net leverage ratio. The 2021 First Lien Credit Agreement is available for working capital and other general corporate purposes and, if drawn, can be repaid at any time without premium or penalty. As of June 30, 2022, we were in compliance with the financial covenants contained in our 2021 First Lien Credit Agreement. There were no outstanding borrowings under the 2021 First Lien Credit Agreement as of June 30, 2022 and December 31, 2021. Bridge Loan Facility On February 24, 2022, LivaNova PLC and its wholly-owned subsidiary, LivaNova USA, Inc., entered into an Incremental Facility Amendment No. 1 to the 2021 First Lien Credit Agreement, relating to a €200 million bridge loan facility (the “Bridge Loan Facility”). On March 16, 2022, LivaNova entered into Amendment No. 2 to the 2021 First Lien Credit Agreement, which converted the available borrowings under the Bridge Loan Facility from €200 million to $220.0 million and converted the EURIBOR rate in the 2021 First Lien Credit Agreement to SOFR. LivaNova delivered a borrowing notice for $220.0 million in connection with the Bridge Loan Facility, which was funded on March 17, 2022. On March 18, 2022, LivaNova PLC, acting through its Italian branch, entered into an Indemnity Letter and an Account Pledge Agreement with Barclays, further to which Barclays issued the SNIA Litigation Guarantee. As security for the SNIA Litigation Guarantee, LivaNova is required to grant cash collateral to Barclays in US dollars in an amount equal to the USD equivalent of 105% of the amount of the SNIA Litigation Guarantee calibrated on a biweekly basis. The proceeds of the Bridge Loan Facility were used by LivaNova to post a portion of the cash collateral supporting the SNIA Litigation Guarantee. The cash held as collateral supporting the SNIA Litigation Guarantee of $297.7 million was classified as restricted cash on the condensed consolidated balance sheet as of June 30, 2022. The Bridge Loan Facility bears interest at an adjusted term SOFR, with a floor of 0.5%, plus 3.5% increasing by 0.25% 15 days after drawing and by an additional 0.5% 90 days after drawing and every 90 days thereafter, with a maximum margin of 5.25% over adjusted SOFR. The effective interest rate of the Bridge Loan Facility at June 30, 2022 was 11.04%. For additional information regarding the SNIA litigation, please refer to “Note 8. Commitments and Contingencies.” Debt discounts and issuance costs related to the Bridge Loan Facility were approximately $4.5 million. Amortization of debt discount and issuance costs for the Bridge Loan Facility was $3.6 million and $4.5 million for the three and six months ended June 30, 2022, respectively, and is included in interest expense on the consolidated statement of income (loss). Outstanding borrowings under the Bridge Loan Facility were $220.0 million as of June 30, 2022. The Bridge Loan Facility was repaid in full on July 6, 2022. Please refer to “Note 15. Subsequent Event” for additional information. 2020 Cash Exchangeable Senior Notes On June 17, 2020, our wholly-owned subsidiary, LivaNova USA, Inc., issued $287.5 million aggregate principal amount of 3.00% Notes (the “Notes”) by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The sale of the Notes resulted in approximately $278.0 million in net proceeds to the Company after deducting issuance costs. Interest is payable semiannually in arrears on June 15 and December 15 of each year. The effective interest rate of the Notes at June 30, 2022 was 9.95%. The Notes mature on December 15, 2025 unless earlier exchanged, repurchased, or redeemed. Debt discounts and issuance costs related to the Notes were approximately $82.0 million and included $75.0 million of discount attributable to the embedded exchange feature, discussed below, and $7.0 million of allocated issuance costs to the Notes related to legal, bank and accounting fees. Amortization of debt discount and issuance costs for the Notes was $3.5 million and $6.9 million for the three and six months ended June 30, 2022, respectively, and is included in interest expense on the consolidated statement of income (loss). The unamortized discount related to the Notes as of June 30, 2022 and December 31, 2021 was $55.4 million and $62.4 million, respectively. Holders of the Notes are entitled to exchange the Notes at any time during specified periods, at their option. This includes the right to exchange the Notes during any calendar quarter, if the last reported sale price of LivaNova’s ordinary shares, with a nominal value of £1.00 per share, is greater than or equal to 130% of the exchange price, or $79.27 per share for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter. The exchange condition was not satisfied during the quarterly period ending June 30, 2022. As a result, we have included our obligations from the Notes and the associated embedded exchange feature derivative as a long-term liability on the consolidated balance sheet as of June 30, 2022. The Notes are exchangeable solely into cash and are not exchangeable into ordinary shares of LivaNova or any other security under any circumstances. The initial exchange rate for the Notes is 16.3980 ordinary shares per $1,000 principal amount of Notes (equivalent to an initial exchange price of approximately $60.98 per share). The exchange rate is subject to adjustment in certain circumstances, as set forth in the indenture governing the Notes. The Company may redeem the Notes at its option, on or after June 20, 2023 and prior to the 51 st scheduled trading day immediately preceding the maturity date, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Additionally, the Company may redeem the Notes at its option, prior to their stated maturity, in whole but not in part, in connection with certain tax-related events. Embedded Exchange Feature The embedded exchange feature of the Notes requires bifurcation from the Notes and is accounted for as a derivative liability. The fair value of the Notes’ embedded exchange feature derivative at the time of issuance was $75.0 million and was recorded as debt discount on the Notes. This discount is amortized as interest expense using the effective interest method over the term of the Notes. The Notes’ embedded exchange feature derivative is carried on the condensed consolidated balance sheets at its estimated fair value and is adjusted at the end of each reporting period, with the unrealized gain or loss reflected within “Foreign exchange and other income/(expense)” in the condensed consolidated statements of income (loss). The fair value of the embedded exchange feature derivative liability was $134.1 million as of June 30, 2022. Capped Call Transactions In connection with the pricing of the Notes, the Company entered into privately negotiated capped call transactions with certain of the initial purchasers of the Notes or their respective affiliates. The capped call transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of LivaNova’s ordinary shares underlying the Notes and are expected generally to offset any cash payments the Company is required to make upon exchange of the Notes in excess of the principal amount thereof in the event that the market value per ordinary share, as measured under the capped call transactions, is greater than the strike price of the capped call transactions, with such offset being subject to an initial cap price of $100.00 per share. The capped call transactions expire on December 15, 2025 and must be settled in cash. If the capped call transactions are converted or redeemed early, settlement occurs at their termination value, which is equal to their fair value at the time of the redemption. The capped call transactions are carried on the condensed consolidated balance sheets as a derivative asset at their estimated fair value and are adjusted at the end of each reporting period, with unrealized gain or loss reflected within “Foreign exchange and other income/(expense)” in the condensed consolidated statements of income (loss). The fair value of the capped call derivative assets was $61.6 million as of June 30, 2022. As of June 30, 2022, the capped call derivative assets are classified as long-term.

Derivatives and Risk Management

Derivatives and Risk Management	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Risk Management	Note 7. Derivatives and Risk Management Due to the global nature of our operations, we are exposed to foreign currency exchange rate fluctuations. We enter into FX derivative contracts to reduce the impact of foreign currency exchange rate fluctuations on earnings and cash flow. We are also exposed to equity price risk in connection with our Notes, including exchange and settlement provisions based on the price of our ordinary shares at exchange or maturity of the Notes. In addition, the capped call transactions associated with the Notes also include settlement provisions that are based on the price of our ordinary shares, subject to a capped price per share. We do not enter into derivative contracts for speculative purposes. We measure all outstanding derivatives each period end at fair value and report the fair value as either financial assets or liabilities on the condensed consolidated balance sheets. At inception of the contract, the derivative is designated as either a freestanding derivative or a hedge. Derivatives that are not designated as hedging instruments are referred to as freestanding derivatives with changes in fair value included in earnings. If the derivative qualifies for hedge accounting, changes in the fair value of the derivative will be recorded in accumulated other comprehensive income (“AOCI”) until the hedged item is recognized in earnings upon settlement/termination. FX derivative gains and losses in AOCI are reclassified to our condensed consolidated statements of income (loss) as shown in the tables below. We evaluate hedge effectiveness at inception. Cash flows from derivative contracts are reported as operating activities on our condensed consolidated statements of cash flows. Freestanding FX Derivative Contracts The gross notional amount of FX derivative contracts not designated as hedging instruments outstanding at June 30, 2022 and December 31, 2021 was $117.2 million and $136.7 million, respectively. These derivative contracts are designed to offset the FX effects in earnings of various intercompany loans and trade receivables. We recorded net gains (losses) for these freestanding derivatives of $4.0 million and $(1.7) million for the three months ended June 30, 2022 and 2021, respectively, and $5.0 million and $5.9 million for the six months ended June 30, 2022 and 2021, respectively. These gains are included in “Foreign exchange and other income/(expense)” in the condensed consolidated statements of income (loss). Counterparty Credit Risk We are exposed to credit risk in the event of non-performance by the counterparties to our derivatives. The two counterparties to the capped call transactions are financial institutions. To limit our credit risk, we selected financial institutions with a minimum long-term investment grade credit rating. Our exposure to the credit risk of the counterparties is not secured by any collateral. If a counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings, with a claim equal to our exposure at that time under the capped call transactions with that counterparty. To manage credit risk with respect to our other derivatives, the Company selects and periodically reviews counterparties based on credit ratings, limits its exposure with respect to each counterparty, and monitors the market positions. However, if one or more of these counterparties were in a liability position to the Company and were unable to meet their obligations, any transactions with the counterparty could be subject to early termination, which could result in substantial losses for the Company. Cash Flow Hedges We utilize FX derivative contracts, designed as cash flow hedges, to hedge the variability of cash flows associated with our 12-month U.S. dollar forecasts of revenues and costs denominated in British Pound, Japanese Yen and the Euro. We transfer to earnings from AOCI the gain or loss realized on the FX derivative contracts at the time of invoicing. The gross notional amounts of open derivative contracts designated as cash flow hedges at June 30, 2022 and December 31, 2021 were as follows (in thousands): Description of Derivative Contract June 30, 2022 December 31, 2021 FX derivative contracts to be exchanged for British Pounds $ 5,416 $ 11,160 FX derivative contracts to be exchanged for Japanese Yen 3,334 6,648 FX derivative contracts to be exchanged for Euros 29,110 58,224 $ 37,860 $ 76,032 After-tax net gain associated with derivatives designated as cash flow hedges recorded in the ending balance of AOCI and the amount expected to be reclassified to earnings in the next 12 months are as follows (in thousands): Description of Derivative Contract After-Tax Net Loss in AOCI as of June 30, 2022 After-Tax Net Loss in AOCI as of June 30, 2022 Expected to be Reclassified to Earnings in Next 12 Months FX derivative contracts $ (2,869) $ (2,869) Pre-tax gains (losses) for derivative contracts designated as cash flow hedges recognized in other comprehensive income (loss) (“OCI”) and the amount reclassified to earnings from AOCI were as follows (in thousands): Three Months Ended June 30, 2022 2021 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other income/(expense) $ (1,116) $ 1,238 $ (621) $ (1,306) FX derivative contracts SG&A — (1,122) — 858 $ (1,116) $ 116 $ (621) $ (448) Six Months Ended June 30, 2022 2021 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings Losses Recognized in OCI Losses Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ (1,758) $ 1,679 $ (2,844) $ (2,802) FX derivative contracts SG&A — (1,510) — 1,543 $ (1,758) $ 169 $ (2,844) $ (1,259) We offset fair value amounts associated with our derivative instruments on our condensed consolidated balance sheets that are executed with the same counterparty under master netting arrangements. Our netting arrangements include a right to set off or net together purchases and sales of similar products in the settlement process. The following tables present the fair value and the location of derivative contracts reported on the condensed consolidated balance sheets (in thousands): June 30, 2022 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) FX derivative contracts Current derivative assets $ 585 Current derivative liabilities $ 3,386 Total derivatives designated as hedging instruments 585 3,386 Derivatives Not Designated as Hedging Instruments FX derivative contracts Current derivative assets 1,935 Current derivative liabilities 3 FX derivative contracts Current derivative liabilities 157 Capped call derivatives Long-term derivative assets 61,608 Embedded exchange feature Long-term derivative liabilities 134,090 Total derivatives not designated as hedging instruments 63,700 134,093 Total derivatives $ 64,285 $ 137,479 December 31, 2021 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) FX derivative contracts Current derivative liabilities $ 243 Current derivative liabilities $ 1,286 Total derivatives designated as hedging instruments 243 1,286 Derivatives Not Designated as Hedging Instruments FX derivative contracts Current derivative liabilities 61 Current derivative liabilities 427 Capped call derivatives Current derivative assets 106,629 Embedded exchange feature Current derivative liabilities 181,700 Total derivatives not designated as hedging instruments 106,690 182,127 Total derivatives $ 106,933 $ 183,413 (1) For the classification of inputs used to evaluate the fair value of our derivatives, refer to “Note 5. Fair Value Measurements.”

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8. Commitments and Contingencies FDA Warning Letter On December 29, 2015, the FDA issued a Warning Letter alleging certain violations of FDA regulations applicable to medical device manufacturers at our Munich, Germany and Arvada, Colorado facilities. The FDA inspected the Munich facility from August 24, 2015 to August 27, 2015 and the Arvada facility from August 24, 2015 to September 1, 2015. On August 27, 2015, the FDA issued a Form 483 identifying two observed non-conformities with certain regulatory requirements at the Munich facility. We did not receive a Form 483 in connection with the FDA’s inspection of the Arvada facility. Following receipt of the Form 483, we provided written responses to the FDA describing corrective and preventive actions that were underway or to be taken to address the FDA’s observations at the Munich facility. The Warning Letter responded in part to our responses and identified other alleged violations related to the manufacture of our 3T Heater-Cooler device that were not previously included in the Form 483. The Warning Letter further stated that our 3T devices and other devices we manufactured at our Munich facility were subject to refusal of admission into the U.S. until resolution of the issues set forth by the FDA in the Warning Letter. The FDA had informed us that the import alert was limited to the 3T devices, but that the agency reserved the right to expand the scope of the import alert if future circumstances warranted such action. The Warning Letter did not request that existing users cease using the 3T device, and manufacturing and shipment of all of our products other than the 3T device were unaffected by the import limitation. To help clarify these issues for current customers, we issued an informational Customer Letter in January 2016 and that same month agreed with the FDA on a process for shipping 3T devices to existing U.S. users pursuant to a certificate of medical necessity program. Finally, the Warning Letter stated that premarket approval applications for Class III devices to which certain Quality System regulation deviations identified in the Warning Letter were reasonably related would not be approved until the violations had been corrected; however, this restriction applied only to the Munich and Arvada facilities, which do not manufacture or design devices subject to Class III premarket approval. On February 25, 2020, LivaNova received clearance for K191402, a 510(k) for the 3T devices that addressed issues contained in the 2015 Warning Letter along with design changes that further mitigate the potential risk of aerosolization. Concurrent with this clearance, (1) 3T devices manufactured in accordance with K191402 will not be subjected to the import alert and (2) LivaNova initiated a correction to distribute the updated Operating Instructions cleared under K191402. With this 510(k) clearance, all actions to remediate the FDA’s inspectional observations in the Warning Letter were complete, and LivaNova awaited the FDA’s close-out inspection. On April 28, 2022, the FDA completed its close-out inspection of the Munich, Germany facility and, at the conclusion of the inspection, issued a Form 483 which contained three inspectional observations in the areas of design validation, process validation and complaint investigations. We submitted a detailed response including our proposed corrective and preventative actions to address the FDA’s observations and a subsequent follow-up to the FDA commenting on the Form 483 observations in the context of our previous actions and remediation efforts to the 2015 Warning Letter, including the January 2016 informational Customer Letter; shipment of products pursuant to our certificate of medical necessity program; and the activities that we conducted to obtain clearance of K191402 for the modified 3T device. While our responses were designed to resolve the outstanding issues raised by the FDA, whether the FDA will accept our responses is uncertain. Refer to “Part II, Item 1A, Risk Factors” in this Form 10-Q for additional information regarding the risks surrounding receipt of the Form 483. CDC and FDA Safety Communications and Company Field Safety Notice On October 13, 2016, the Center for Disease Control (the “CDC”) and the FDA separately released safety notifications regarding the 3T devices. The CDC’s Morbidity and Mortality Weekly Report (“MMWR”) and Health Advisory Notice (“HAN”) reported that tests conducted by the CDC and its affiliates indicate that there appears to be genetic similarity between both patient and 3T device strains of the non-tuberculous mycobacterium (“NTM”) bacteria M. chimaera isolated in hospitals in Iowa and Pennsylvania. Citing the geographic separation between the two hospitals referenced in the investigation, the report asserts that 3T devices manufactured prior to August 18, 2014 could have been contaminated during the manufacturing process. The CDC’s HAN and FDA’s Safety Communication, issued contemporaneously with the MMWR report, each assess certain risks associated with 3T devices and provide guidance for providers and patients. The CDC notification states that the decision to use the 3T device during a surgical operation is to be taken by the surgeon based on a risk approach and on patient need. Both the CDC’s and FDA’s communications confirm that 3T devices are critical medical devices and enable doctors to perform life-saving cardiac surgery procedures. Also on October 13, 2016, concurrent with the CDC’s HAN and FDA’s Safety Communication, we issued a Field Safety Notice Update for U.S. users of 3T devices to proactively and voluntarily contact facilities to aid in implementation of the CDC and FDA recommendations. In the fourth quarter of 2016, we initiated a program to provide existing 3T device users with a new loaner 3T device at no charge pending regulatory approval and implementation of additional risk mitigation strategies worldwide, including a vacuum canister and internal sealing upgrade program and a deep disinfection service. In April 2017, we obtained CE Mark in Europe for the design change of the 3T device, and in October 2018, the FDA concluded that we could commence the vacuum canister and internal sealing upgrade program in the U.S. On February 25, 2020, LivaNova received clearance for K191402, a 510(k) for the 3T devices that addressed issues contained in the 2015 Warning Letter along with design changes that further mitigate the potential risk of aerosolization. We are in the process of completing and closing out all recall activities with the FDA. While our vacuum canister and internal sealing upgrade program and deep cleaning service in the U.S. are substantially complete, these services will continue as a servicing option outside of the U.S. On December 31, 2016, we recognized a liability for our product remediation plan related to our 3T device. We concluded that it was probable that a liability had been incurred upon management’s approval of the plan and the commitments made by management to various regulatory authorities globally during the fourth quarter of 2016, and furthermore, the cost associated with the plan was reasonably estimable. At June 30, 2022, the product remediation liability was $0.7 million. Saluggia Site Hazardous Substances LivaNova Site Management S.r.l. (“LSM”), formerly a subsidiary of Sorin, one of the companies that merged into LivaNova PLC in 2015, manages site services for the campus in Saluggia, Italy. In addition to a LivaNova manufacturing facility, the Saluggia campus is also the location of manufacturing facilities of third parties, a cafeteria for workers, and storage facilities for hazardous substances and equipment previously used in a nuclear research center, later turned nuclear medicine business, between the 1960s and the late 1990s. Pursuant to authorization from the Italian government, LSM has, and continues to, perform ordinary maintenance, secure the facilities, monitor air and water quality and file applicable reports with the competent environmental authorities. During 2020, LSM received correspondence from ISIN (a sub-body of the Italian Ministry of Economic Development) requesting that within five years, LSM demonstrate the financial capacity to meet its obligations under Italian law to clean and dismantle any contaminated buildings and equipment as well as to deliver hazardous substances to a national repository. This repository will be built by the Italian government at a location and time yet to be determined. ISIN subsequently published Technical Guide n. 30, which identifies the technical criteria, and general safety and protection requirements for the design, construction, operation and dismantling of temporary storage facilities for the hazardous substances. In January 2021, a list of 67 potential sites for the national repository was published. Although there is no legal obligation to begin any work or deliver the hazardous substances, as the performance of these obligations is contingent on the construction of the as-yet unbuilt national repository, based on the aforementioned factors, the Company concluded its obligation to clean, dismantle, and deliver any hazardous substances to a national repository is probable and reasonably estimable. The estimated liability as of June 30, 2022 was $35.9 million, which represented the low end of the estimated range of loss of $35.9 million to $45.6 million. The estimated liability as of December 31, 2021 was $39.3 million. The decrease in the liability from December 31, 2021 was primarily due to the effects of foreign currency changes during the six months ended June 30, 2022. Litigation Product Liability The Company is currently involved in litigation involving our 3T device. The litigation includes federal multi-district litigation in the U.S. District Court for the Middle District of Pennsylvania, various U.S. state court cases and cases in jurisdictions outside the U.S. A class action, filed in February 2016 in the U.S. District Court for the Middle District of Pennsylvania, consisting of all Pennsylvania residents who underwent open heart surgery at WellSpan York Hospital and Penn State Milton S. Hershey Medical Center between 2011 and 2015 and who currently are asymptomatic for NTM infection, was dismissed on July 16, 2021. On March 29, 2019, we announced a settlement framework that provides for a comprehensive resolution of the personal injury cases pending in the multi-district litigation in U.S. federal court, the related class action in federal court, as well as certain cases in state courts across the United States. The agreement, which makes no admission of liability, is subject to certain conditions, including acceptance of the settlement by individual claimants and provides for a total payment of up to $225 million to resolve the claims covered by the settlement. Per the agreed-upon terms, the first payment of $135 million was paid into a qualified settlement fund in July 2019 and the second payment of $90 million was paid in January 2020. Cases covered by the settlement are being dismissed as amounts are disbursed to individual plaintiffs from the qualified settlement fund. Cases in state courts in the U.S. and in jurisdictions outside the U.S. continue to progress. As of August 3, 2022, including the cases encompassed in the settlement framework described above that have not yet been dismissed, we were aware of approximately 90 filed and unfiled claims worldwide, with the majority of the claims in various federal or state courts throughout the United States. This number includes six cases that have settled but have not yet been dismissed. The complaints generally seek damages and other relief based on theories of strict liability, negligence, breach of express and implied warranties, failure to warn, design and manufacturing defect, fraudulent and negligent misrepresentation or concealment, unjust enrichment, and violations of various state consumer protection statutes. At June 30, 2022, the provision for these matters was $36.9 million. While the amount accrued represents our best estimate for those filed and unfiled claims that we believe are both probable and estimable at this time, and which are a subset of the filed and unfiled claims worldwide of which we are currently aware, the actual liability for resolution of these matters may vary from our estimate. The remaining claims for which a provision has not been recorded are remote or the potential loss is not estimable at this time. Changes in the carrying amount of the litigation provision liability are as follows (in thousands): Total litigation provision liability at December 31, 2021 $ 39,470 Payments (2,773) Adjustments (1) 709 FX and other (517) Total litigation provision liability at June 30, 2022 36,889 Less current portion of litigation provision liability at June 30, 2022 30,960 Long-term portion of litigation provision liability at June 30, 2022 (2) $ 5,929 (1) Adjustments to the litigation provision are included within other operating expenses on the condensed consolidated statements of income (loss). (2) Included within other long-term liabilities on the condensed consolidated balance sheet. Environmental Liability Sorin was created as a result of a spin-off (the “Sorin spin-off”) from SNIA in January 2004, and in October 2015, Sorin was merged into LivaNova. SNIA subsequently became insolvent, and the Italian Ministry of the Environment and the Protection of Land and Sea (the “Italian Ministry of the Environment”), sought compensation from SNIA in an aggregate amount of approximately $4 billion for remediation costs relating to the environmental damage at chemical sites previously operated by SNIA’s other subsidiaries. There are proceedings relating to the SNIA bankruptcy to which we are not a party in the Bankruptcy Court of Udine and the Bankruptcy Court of Milan. In September 2011, the Bankruptcy Court of Udine held that the Italian Ministry of the Environment and other Italian government agencies (the “Public Administrations”) were not creditors of either SNIA or its subsidiaries in connection with their claims in the Italian insolvency proceedings. The Public Administrations appealed. In January 2016, the Court of Udine rejected the appeal, and the Public Administrations appealed to the Supreme Court. Similarly, in July 2014, the Bankruptcy Court of Milan held that the Public Administrations were not creditors of either SNIA or its subsidiaries. The Public Administrations appealed. In April 2022, Bankruptcy Court of Milan declared the Public Administrations to be a non-privileged creditor of SNIA for up to €454 million, and the Public Administrations appealed to the Supreme Court. In January 2012, SNIA filed a civil action against Sorin in the Civil Court of Milan asserting joint liability of a parent and a spun-off company; the Public Administrations entered voluntarily into the proceeding, asking Sorin, as jointly liable with SNIA, to pay compensation for SNIA’s environmental damages. On April 1, 2016, the Court of Milan dismissed all legal actions of SNIA and of the Public Administrations further requiring the Public Administrations to pay Sorin approximately €292,000 (approximately $304,103 as of June 30, 2022) for legal fees. The Public Administrations appealed the 2016 decision to the Court of Appeal of Milan (“Court of Appeal”). On March 5, 2019, the Court of Appeal issued a partial decision on the merits declaring Sorin/LivaNova jointly liable with SNIA for SNIA’s environmental liabilities in an amount up to the fair value of the net worth received by Sorin because of the Sorin spin-off, an estimated €572.1 million (approximately $595.8 million as of June 30, 2022). We appealed the partial decision on liability to the Italian Supreme Court in August 2019. In November 2021, the Court of Appeal delivered the remainder of its decision, ordering LivaNova to pay damages of approximately €453.6 million (approximately $472.4 million as of June 30, 2022). We appealed the decision on damages in December 2021. The Italian Supreme Court scheduled a hearing for October 5, 2022 to address the appeals of liability and damages. On February 21, 2022, the Court of Appeal notified the Company that it granted the Company a suspension with respect to the payment of damages until a decision has been reached on the appeal to the Italian Supreme Court. This suspension was subject to our providing a first demand bank guarantee of €270.0 million (approximately $281.2 million as of June 30, 2022) within 30 calendar days, and on March 21, 2022, LivaNova delivered the guarantee, thereby satisfying the condition. Refer to “Note 6. Financing Arrangements” for information on the financing of the guarantee. In 2011, Caffaro, a SNIA subsidiary, sold its Brescia chemical business to Caffaro Brescia, a third party belonging to the Todisco group, and as part of the acquisition, Caffaro Brescia agreed to secure hydraulic barriers at the site and maintain existing environmental security measures. In September 2020, Caffaro Brescia declared it was withdrawing from its agreement to maintain the environmental measures. In January 2021, we (in addition to Caffaro Brescia, and other non-LivaNova entities) received an administrative order (“Order”) from the Italian Ministry of the Environment requiring us to ensure the maintenance of the environmental measures and to guarantee that such works remain fully operational, the annual management and maintenance for which is estimated at approximately €1 million per year. LivaNova’s receipt of the Order appears to be based on the aforementioned Court of Appeal decision regarding our alleged joint liability with SNIA for SNIA’s environmental liabilities. Our response, dated February 16, 2021, disputes the grounds upon which the Order is based. We also appealed the Order in the Administrative Court in Brescia. We have not recognized a liability in connection with these related matters because any potential loss is not currently probable. Contract Litigation / Claims On November 25, 2019, LivaNova received notice of a lawsuit initiated by former members of Caisson Interventional, LLC (“Caisson”), a subsidiary of the Company acquired in 2017. The lawsuit, Todd J. Mortier, as Member Representative of the former Members of Caisson Interventional, LLC v. LivaNova USA, Inc., was filed in the United States District Court for the District of Minnesota. The complaint alleged (i) breach of contract, (ii) breach of the covenant of good faith and fair dealing and (iii) unjust enrichment in connection with the Company’s operation of Caisson’s Transcatheter Mitral Valve Replacement (“TMVR”) program and the Company’s November 20, 2019 announcement that it was ending the TMVR program at the end of 2019. The lawsuit sought damages arising out of the 2017 acquisition agreement, including various regulatory milestone payments. In May 2022, the District Court granted LivaNova’s motion for summary judgment; in response, Caisson subsequently filed a notice of appeal to the Eighth Circuit Court of Appeal. We intend to vigorously defend this claim. The Company has not recognized a liability related to this matter because any potential loss is not currently probable or reasonably estimable. Please refer to “Note 3. Divestiture of Heart Valve Business” for information regarding a demand letter received by the Company from Mitral on July 29, 2022. The Company has not recognized a liability related to this matter because any potential loss is not currently probable. Other Matters Additionally, we are the subject of various pending or threatened legal actions and proceedings that arise in the ordinary course of our business. These matters are subject to many uncertainties and outcomes that are not predictable and that may not be known for extended periods of time. Since the outcome of these matters cannot be predicted with certainty, the costs associated with them could have a material adverse effect on our consolidated net income, financial position or liquidity.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 9. Stockholders' Equity The tables below present the condensed consolidated statements of stockholders’ equity as of and for the three and six months ended June 30, 2022 and 2021 (in thousands): Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Accumulated Deficit (1) Total Stockholders' Equity (1) March 31, 2022 53,764 $ 82,298 $ 2,121,098 $ (619) $ (16,132) $ (894,791) $ 1,291,854 Stock-based compensation plans 46 61 12,160 222 — — 12,443 Net income — — — — — 16,444 16,444 Other comprehensive loss — — — — (38,738) — (38,738) June 30, 2022 53,810 $ 82,359 $ 2,133,258 $ (397) $ (54,870) $ (878,347) $ 1,282,003 March 31, 2021 49,455 $ 76,310 $ 1,770,407 $ (798) $ 1,938 $ (792,727) $ 1,055,130 Stock-based compensation plans 68 95 8,706 93 — — 8,894 Net loss — — — — — (56,487) (56,487) Other comprehensive income — — — — 21,137 — 21,137 June 30, 2021 49,523 $ 76,405 $ 1,779,113 $ (705) $ 23,075 $ (849,214) $ 1,028,674 Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Accumulated Deficit (1) Total Stockholders' Equity (1) December 31, 2021 53,762 $ 82,295 $ 2,117,961 $ (650) $ (7,177) $ (897,784) $ 1,294,645 Stock-based compensation plans 48 64 15,297 253 — — 15,614 Net income — — — — — 19,437 19,437 Other comprehensive loss — — — — (47,693) — (47,693) June 30, 2022 53,810 $ 82,359 $ 2,133,258 $ (397) $ (54,870) $ (878,347) $ 1,282,003 December 30, 2020 49,447 $ 76,300 $ 1,768,156 $ (1,034) $ 27,809 $ (761,966) $ 1,109,265 Stock-based compensation plans 76 105 10,957 329 — — 11,391 Net loss — — — — — (87,248) (87,248) Other comprehensive loss — — — — (4,734) — (4,734) June 30, 2021 49,523 $ 76,405 $ 1,779,113 $ (705) $ 23,075 $ (849,214) $ 1,028,674 (1) Accumulated deficit and total stockholders’ equity as of June 30, 2021 and net loss for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.” The table below presents the change in each component of AOCI, net of tax, and the reclassifications out of AOCI into net income for the six months ended June 30, 2022 and 2021 (in thousands): Change in Unrealized Gain (Loss) on Derivatives Foreign Currency Translation Adjustments Gain (Loss) (1) Total December 31, 2021 $ (945) $ (6,232) $ (7,177) Other comprehensive loss before reclassifications, before tax (1,758) (45,766) (47,524) Tax benefit — — — Other comprehensive loss before reclassifications, net of tax (1,758) (45,766) (47,524) Reclassification of gain from accumulated other comprehensive loss, before tax (169) — (169) Reclassification of tax benefit — — — Reclassification of gain from accumulated other comprehensive loss, after tax (169) — (169) Net current-period other comprehensive loss, net of tax (1,927) (45,766) (47,693) June 30, 2022 $ (2,872) $ (51,998) $ (54,870) December 31, 2020 $ 2,319 $ 25,490 $ 27,809 Other comprehensive loss before reclassifications, before tax (2,844) (3,530) (6,374) Tax benefit 683 — 683 Other comprehensive loss before reclassifications, net of tax (2,161) (3,530) (5,691) Reclassification of loss from accumulated other comprehensive income, before tax 1,259 — 1,259 Reclassification of tax benefit (302) — (302) Reclassification of loss from accumulated other comprehensive income, after tax 957 — 957 Net current-period other comprehensive loss, net of tax (1,204) (3,530) (4,734) June 30, 2021 $ 1,115 $ 21,960 $ 23,075 (1) Taxes are not provided for foreign currency translation adjustments as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned.

Stock-Based Incentive Plans

Stock-Based Incentive Plans	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Incentive Plans	Note 10. Stock-Based Incentive Plans Stock-based incentive plans compensation expense is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Service-based restricted stock units (“RSUs”) $ 5,882 $ 5,205 $ 11,226 $ 10,047 Service-based stock appreciation rights (“SARs”) 3,720 3,064 6,658 6,386 Market performance-based restricted stock units 1,003 898 1,854 1,661 Operating performance-based restricted stock units 611 239 1,396 506 Employee share purchase plan 293 510 631 852 Total stock-based compensation expense $ 11,509 $ 9,916 $ 21,765 $ 19,452 Stock-based awards may be granted under the 2015 Incentive Award Plan (the “2015 Plan”) and the 2022 Incentive Award Plan (the “2022 Plan”) in the form of stock options, SARs, RSUs and other stock-based and cash-based awards. As of June 30, 2022, there were 56,428 shares available for future grants to our Non-Executive Directors under the 2015 Plan and 1,900,000 shares pursuant to Options or Stock Appreciation Rights and 1,173,352 shares pursuant to other types of awards available for future grants to our employees under the 2022 Plan. During the six months ended June 30, 2022, we issued stock-based compensatory awards with terms approved by the Compensation Committee of our Board of Directors. The awards with service conditions generally vest ratably from two years and are subject to forfeiture unless service conditions are met. The market performance-based awards that were issued cliff vest after three years subject to the rank of our total shareholder return for the three-year period ending December 31, 2024 relative to the total shareholder returns for a peer group of companies. The adjusted free cash flow and return on invested capital operating performance-based awards that were issued cliff vest after three years subject to the achievement of certain thresholds of cumulative results for the three-year period ending December 31, 2024. Compensation expense related to awards granted during 2022 for the six months ended June 30, 2022 was $3.0 million. Stock-based compensation agreements issued during the six months ended June 30, 2022, representing potential shares and their weighted average grant date fair values by type follows (shares in thousands, fair value in dollars): Six Months Ended June 30, 2022 Shares Weighted Average Grant Date Fair Value Service-based SARs 553,050 $ 34.13 Service-based RSUs 291,330 $ 79.04 Market performance-based RSUs 44,180 $ 103.02 Operating performance-based RSUs 44,174 $ 82.04

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes Our effective income tax rate for the three and six months ended June 30, 2022 was 13.2% and 20.6%, respectively, compared with (7.4)% and (8.1)%, respectively, for the three and six months ended June 30, 2021. Our effective income tax rate fluctuates based on, among other factors, changes in pretax income in countries with varying statutory tax rates, valuation allowances, tax credits and incentives, and unrecognized tax benefits associated with uncertain tax positions. We continually assess the realizability of our worldwide deferred tax asset and valuation allowance positions, and when the need arises, we establish or release valuation allowances accordingly. Compared with the three months ended June 30, 2021, the change in the effective tax rate for the three months ended June 30, 2022 was primarily attributable to discrete items and changes in income before tax in countries with varying statutory tax rates as compared to the discrete tax impact of the sale of the Heart Valve business during the three months ended June 30, 2021. Compared with the six months ended June 30, 2021, the change in the effective tax rate for the six months ended June 30, 2022 was primarily attributable to discrete items and changes in income before tax in countries with varying statutory tax rates as compared to discrete items and the discrete tax impact of the sale of the Heart Valve business during the six months ended June 30, 2021. We operate in multiple jurisdictions throughout the world, and our tax returns are periodically audited or subjected to review by tax authorities. As a result, there is an uncertainty in income taxes recognized in our financial statements. Tax benefits totaling $1.6 million and $1.7 million were unrecognized as of June 30, 2022 and December 31, 2021, respectively. It is reasonably possible that, within the next twelve months, due to the settlement of uncertain tax positions with various tax authorities and the expiration of statutes of limitations, unrecognized tax benefits could decrease by up to approximately $1.0 million.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Note 12. Earnings Per Share Reconciliation of the shares used in the basic and diluted earnings per share computations for the three and six months ended June 30, 2022 and 2021 are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Basic weighted average shares outstanding 53,506 48,928 53,420 48,833 Add effects of share-based compensation instruments (1) 574 — 724 — Diluted weighted average shares outstanding 54,080 48,928 54,144 48,833 (1) Excluded from the computation of diluted earnings per share were stock options, SARs and restricted share units totaling 2.2 million and 3.9 million for the three months ended June 30, 2022 and 2021, respectively, and 2.2 and 4.1 million for the six months ended June 30, 2022 and 2021, respectively, because to include them would have been anti-dilutive under the treasury stock method.

Geographic and Segment Informat

Geographic and Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Geographic and Segment Information	Note 13. Geographic and Segment Information We identify operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources, developing and executing our strategy, and assessing performance. We have three reportable segments: Cardiopulmonary, Neuromodulation and ACS. Our Cardiopulmonary segment is engaged in the development, production and sale of cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae and other related accessories. Our Neuromodulation segment is engaged in the design, development and marketing of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (“DRE”) and difficult-to-treat depression (“DTD”). Neuromodulation products include the VNS Therapy System, which consists of an implantable pulse generator, a lead that connects the generator to the vagus nerve, and other accessories. It also includes the development and management of clinical testing of our aura6000 System for treating obstructive sleep apnea (“OSA”). This device stimulates the hypoglossal nerve, which in turn, engages certain muscles in the tongue in order to open the airway while a patient is sleeping. Our Neuromodulation segment also includes the VITARIA System for treating heart failure by stimulating the right vagus nerve. Our Advanced Circulatory Support segment is engaged in the development, production and sale of leading-edge temporary life support products. Our ACS products, which comprise the LifeSPARC platform, simplify temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The LifeSPARC platform includes a common compact console and pump that provides temporary support for emergent rescue patients in a variety of settings. Our ACS segment also includes the Hemolung Respiratory Assist System (“Hemolung RAS”), which was acquired in May 2022 as part of the acquisition of ALung. “Other” includes corporate shared service expenses for finance, legal, human resources, information technology and corporate business development. For 2021, other also includes the results of our Heart Valves business, which was disposed of on June 1, 2021. Net sales of our reportable segments includes revenues from the sale of products that each reportable segment develops and manufactures or distributes. We define segment income as operating income before merger and integration, restructuring and amortization of intangibles. We operate under three geographic regions: U.S., Europe, and Rest of World. The table below presents net sales by operating segment and geographic region (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cardiopulmonary United States $ 37,865 $ 37,388 $ 75,961 $ 73,147 Europe 33,159 35,133 65,226 65,759 Rest of World 54,796 45,355 101,708 87,689 125,820 117,876 242,895 226,595 Neuromodulation United States 91,431 91,779 178,641 174,079 Europe 13,710 14,604 26,166 26,283 Rest of World 12,654 11,253 23,215 20,973 117,795 117,636 228,022 221,335 Advanced Circulatory Support United States 8,790 12,964 19,753 25,524 Europe 503 178 1,106 406 Rest of World 59 133 176 337 9,352 13,275 21,035 26,267 Other (1) United States — 2,212 — 4,929 Europe — 6,123 — 14,407 Rest of World 1,184 7,361 2,374 18,553 1,184 15,696 2,374 37,889 Totals United States 138,086 144,343 274,355 277,679 Europe (2) 47,372 56,038 92,498 106,855 Rest of World 68,693 64,102 127,473 127,552 Total (3) $ 254,151 $ 264,483 $ 494,326 $ 512,086 (1) For 2021, other primarily includes the net sales of the Company’s Heart Valves business, which was disposed of on June 1, 2021. (2) Europe includes those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in Rest of World. (3) No single customer represented over 10% of our consolidated net sales. No country’s net sales exceeded 10% of our consolidated sales except for the U.S. The table below presents a reconciliation of segment income (loss) to consolidated income (loss) before tax (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 (1) 2022 2021 (1) Cardiopulmonary $ 3,644 $ (25,099) $ 10,539 $ (23,657) Neuromodulation 51,360 38,156 88,838 72,239 Advanced Circulatory Support 3,485 (1,311) (1,953) 1,082 Other (2) (19,450) (37,634) (42,532) (67,829) Total reportable segment income (loss) 39,039 (25,888) 54,892 (18,165) Other expenses (3) 7,283 10,374 13,631 23,795 Operating income (loss) 31,756 (36,262) 41,261 (41,960) Interest expense (14,388) (16,515) (22,228) (32,451) Foreign exchange and other income/(expense) 1,633 239 5,537 (6,204) Income (loss) before tax $ 19,001 $ (52,538) $ 24,570 $ (80,615) (1) Segment income for the three and six months ended June 30, 2021 has been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.” (2) Other includes corporate shared service expenses for finance, legal, human resources, information technology and corporate business development. For 2021, other also includes the results of the Company’s Heart Valves business, which was disposed of on June 1, 2021. (3) Other expenses primarily consist of amortization of intangible assets, merger and integration expense and restructuring expense. Assets by segment are as follows (in thousands): June 30, 2022 December 31, 2021 Cardiopulmonary $ 860,410 $ 921,481 Neuromodulation 651,085 646,394 Advanced Circulatory Support 259,515 231,846 Other 565,235 401,230 Total $ 2,336,245 $ 2,200,951 Capital expenditures by segment are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cardiopulmonary $ 3,213 $ 2,671 $ 5,042 $ 5,720 Neuromodulation 46 51 130 91 Advanced Circulatory Support — 528 684 1,084 Other 2,604 2,882 5,587 4,351 Total $ 5,863 $ 6,132 $ 11,443 $ 11,246 The changes in the carrying amount of goodwill by segment for the six months ended June 30, 2022 were as follows (in thousands): Cardiopulmonary Neuromodulation Advanced Circulatory Support Total December 31, 2021 $ 398,245 $ 398,754 $ 102,526 $ 899,525 Goodwill as a result of acquisition — — 25,893 25,893 Foreign currency adjustments (27,348) — — (27,348) June 30, 2022 $ 370,897 $ 398,754 $ 128,419 $ 898,070 Property, plant and equipment, net by geography are as follows (in thousands): June 30, 2022 December 31, 2021 United States $ 62,704 $ 60,852 Europe 76,309 85,313 Rest of World 4,299 3,901 Total $ 143,312 $ 150,066

Supplemental Financial Informat

Supplemental Financial Information	6 Months Ended
	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Supplemental Financial Information	Note 14. Supplemental Financial Information Inventories consisted of the following (in thousands): June 30, 2022 December 31, 2021 Raw materials $ 53,019 $ 43,958 Work-in-process 18,227 14,161 Finished goods 48,169 47,721 $ 119,415 $ 105,840 As of June 30, 2022 and December 31, 2021, inventories included adjustments totaling $9.0 million and $8.9 million, respectively, to record balances at lower of cost or net realizable value. Accrued liabilities and other consisted of the following (in thousands): June 30, 2022 December 31, 2021 Operating lease liabilities $ 10,245 $ 11,261 Contract liabilities 9,097 8,419 Amount payable to Gyrus Capital S.A. 8,767 11,418 Legal and other administrative costs 8,524 8,948 Research and development costs 6,065 5,329 Contingent consideration (1) 5,552 11,552 Provisions for agents, returns and other 1,700 2,535 Other accrued expenses 34,002 29,475 $ 83,952 $ 88,937 (1) Refer to “Note 5. Fair Value Measurements” As of June 30, 2022 and December 31, 2021, contract liabilities totaling $11.8 million and $9.8 million, respectively, were included within accrued liabilities and other long-term liabilities on the condensed consolidated balance sheets. The table below presents the items included within “Foreign exchange and other income/(expense)” on the condensed consolidated statements of income (loss) (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Exchangeable Notes fair value adjustment (1) $ 36,570 $ (26,048) $ 47,610 $ (52,384) Capped call fair value adjustment (1) (35,109) 19,408 (45,021) 31,957 Investment revaluation (2) — — — 4,640 Dividend Income (2) — 3,133 — 3,133 Other derivative liabilities fair value adjustment — 923 — 4,090 Foreign exchange rate fluctuations 341 1,544 3,132 1,134 Interest income 57 189 77 115 Other (226) 1,090 (261) 1,111 Foreign exchange and other income/(expense) $ 1,633 $ 239 $ 5,537 $ (6,204) (1) Refer to “Note 5. Fair Value Measurements” (2) Refer to “Note 4. Investments” The table below presents a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the amounts shown on the condensed consolidated statement of cash flows (in thousands): June 30, 2022 December 31, 2021 Cash and cash equivalents $ 109,022 $ 207,992 Restricted cash (1) 297,747 — Cash, cash equivalents and restricted cash $ 406,769 $ 207,992 (1) Restricted cash represents funds held as collateral for the SNIA Litigation Guarantee. Refer to “Note 8. Commitments and Contingencies.”

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Event	Note 15. Subsequent Event On July 6, 2022, LivaNova and its wholly-owned subsidiary, LivaNova USA, Inc. ( “LivaNova USA”), entered into a new incremental facility amendment (the “Incremental Amendment No. 2”) to its 2021 First Lien Credit Agreement. The Incremental Amendment No. 2 provides for LivaNova USA to, among other things, obtain commitments for term loan facilities from a syndicate of lenders in an aggregate principal amount of $350 million consisting of (i) an initial term loan facility in an aggregate principal amount of $300 million (the “Initial Term Facility”) and (ii) a delayed draw term loan facility in an additional aggregate principal amount of $50 million, which are available in one single drawing on or after July 6 until the date that is nine months after such date (the “Delayed Draw Term Facility” and, together with the Initial Term Facility, the “Term Facilities”). Proceeds of the Initial Term Facility were used to repay in full the Bridge Loan Facility on July 6, 2022, with the remainder to be used for general corporate purposes of the Company. The Term Facilities have a maturity of the earlier of (i) five years or (ii) 91 days prior to December 15, 2025, the maturity date of the Notes, unless by that date LivaNova USA will have either redeemed or refinanced the Notes, or set aside an amount of cash equal to the then-outstanding principal amount of the Notes. The Term Facilities bear interest at a rate equal to an adjusted term SOFR (or, alternatively, the Alternate Base Rate) plus a variable margin based on the Company’s consolidated Total Net Leverage Ratio. As of the date of effectiveness of the Incremental Amendment No. 2, the applicable margin over Adjusted SOFR was equal to 3.50% per annum. The Term Facilities are subject to an original issue discount of 1.5% of their principal amount. The Delayed Draw Term Facility also contemplates the payment of commitment fees at a variable percentage based on the Company’s Total Net Leverage Ratio. As of the date of effectiveness of the Incremental Amendment No. 2, the applicable commitment fee percentage was equal to 0.50% per annum. The Term Facilities are subject to quarterly amortization, based on the following amortization schedule: (i) year one: 2.5%; (ii) year two: 5.0%; (ii) year three: 5.00%; (iv) year four: 7.5%; and (v) year five: 10.0%, with the remainder to be paid at maturity. The 2021 First Lien Credit Agreement, as amended, contains customary representations, warranties and covenants, including the requirement to maintain a Senior Secured First Lien Net Leverage Ratio, calculated as the ratio of Consolidated Senior Secured Indebtedness to Consolidated EBITDA, as defined in the credit agreement, for the period of four consecutive fiscal quarters ended on the calculation date, of less than 3.50 to 1.00 and an interest coverage ratio of not less than 3.00 to 1.00.

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Financial Statements (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of LivaNova as of, and for the three and six months ended June 30, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova at December 31, 2021 has been derived from audited financial statements contained in our 2021 Form 10-K, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries, for the three and six months ended June 30, 2022, and are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying our 2021 Form 10-K.
Reclassifications	ReclassificationsWe have reclassified certain prior period amounts on the condensed consolidated statements of income (loss), the condensed consolidated balance sheets and the condensed consolidated statements of cash flows for comparative purposes. These reclassifications did not have a material effect on our financial condition, results of operations or cash flows.
Restricted Cash	Restricted CashThe Company classifies cash that is not available for use in its operations as restricted cash within current assets on the condensed consolidated balance sheet.
Derivatives	If the derivative qualifies for hedge accounting, changes in the fair value of the derivative will be recorded in accumulated other comprehensive income (“AOCI”) until the hedged item is recognized in earnings upon settlement/termination. FX derivative gains and losses in AOCI are reclassified to our condensed consolidated statements of income (loss) as shown in the tables below. We evaluate hedge effectiveness at inception. Cash flows from derivative contracts are reported as operating activities on our condensed consolidated statements of cash flows.

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Prior Period Reclassifications on the Condensed Consolidated Statements of Income (Loss)	Consolidated Statements of Income (Loss) Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Cost of sales $ 90,803 $ 1,401 $ 92,204 $ 173,723 $ 2,676 $ 176,399 Operating loss (34,861) (1,401) (36,262) (39,284) (2,676) (41,960) Loss before tax (51,137) (1,401) (52,538) (77,939) (2,676) (80,615) Income tax expense 4,140 (232) 3,908 6,996 (444) 6,552 Net loss (55,318) (1,169) (56,487) (85,016) (2,232) (87,248) Basic and diluted loss per share $ (1.13) $ (0.02) $ (1.15) $ (1.74) $ (0.05) $ (1.79) Consolidated Statements of Comprehensive Income (Loss) Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Net loss $ (55,318) $ (1,169) $ (56,487) $ (85,016) $ (2,232) $ (87,248) Total comprehensive loss (34,181) (1,169) (35,350) (89,750) (2,232) (91,982) Consolidated Statements of Stockholders’ Equity As Previously Reported Adjustments As Revised Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity June 30, 2021 $ (837,418) $ 1,040,470 $ (11,796) $ (11,796) $ (849,214) $ 1,028,674 Consolidated Statements of Cash Flows Six Months Ended June 30, 2021 As Previously Reported Adjustments As Revised Net loss $ (85,016) $ (2,232) $ (87,248) Deferred tax expense (benefit) 1,357 (444) 913 Changes in operating assets and liabilities: Inventories 1,221 2,676 3,897 Net cash used in operating activities 45,111 — 45,111

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table presents the acquisition date fair value of the consideration transferred and the fair value of our interest in ALung prior to the acquisition (in thousands): Cash and other considerations $ 15,586 Contingent consideration 26,369 Fair value of consideration transferred $ 41,955
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the preliminary purchase price allocation at fair value for the ALung acquisition (in thousands): Purchase Price Allocation Developed technology - 15-year life $ 13,950 Goodwill 25,893 Other assets and liabilities, net 2,112 Net assets acquired $ 41,955
Significant Unobservable Inputs Related to Contingent Consideration	The sales-based earnout was valued using projected sales from our internal strategic plan and is a Level 3 fair value measurement, which includes the following significant unobservable inputs (in thousands): ALung Acquisition Fair value at May 2, 2022 Valuation Technique Unobservable Input Ranges Sales-based earnout $ 26,369 Monte Carlo simulation Risk-adjusted discount rate 9.7% - 11.1% Credit risk discount rate 6.4% - 8.0% Revenue volatility 38.5% Projected years of earnout 2023 - 2027 ImThera Acquisition Valuation Technique Unobservable Input Inputs Regulatory milestone-based payment Discounted cash flow Discount rate 11.8% Probability of payment 85% Projected payment year 2024 Sales-based earnout Monte Carlo simulation Risk-adjusted discount rate 14.4% Credit risk discount rate 12.4% - 13.4% Revenue volatility 32.5% Probability of payment 85% Projected years of earnout 2025 - 2028 The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of June 30, 2022: TandemLife Acquisition Valuation Technique Unobservable Input Inputs Regulatory milestone-based payment Discounted cash flow Discount rate 10.1% Probability of payment 45% Projected payment year 2023 The ALung business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain sales-based thresholds associated with sales of products. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of June 30, 2022: ALung Acquisition Valuation Technique Unobservable Input Inputs Sales-based earnout Monte Carlo simulation Risk-adjusted discount rate 10.4% - 11.2% Credit risk discount rate 11.0% - 13.2% Revenue volatility 37.5% Projected years of earnout 2023 - 2027

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands): Fair Value as of June 30, 2022 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - designated as cash flow hedges (foreign currency exchange rate “FX”) $ 585 $ — $ 585 $ — Derivative assets - freestanding instruments (FX) 2,092 — 2,092 — Derivative assets - capped call derivatives 61,608 — — 61,608 Convertible notes receivable 278 — — 278 $ 64,563 $ — $ 2,677 $ 61,886 Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 3,386 $ — $ 3,386 $ — Derivative liabilities - freestanding instruments (FX) 3 — 3 — Derivative liabilities - embedded exchange feature 134,090 — — 134,090 Contingent consideration arrangements 97,392 — — 97,392 $ 234,871 $ — $ 3,389 $ 231,482 Fair Value as of December 31, 2021 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - designated as cash flow hedges (foreign currency exchange rate “ FX ” ) $ 243 $ — $ 243 $ — Derivative assets - freestanding instruments (FX) 61 — 61 — Derivative assets - capped call derivatives 106,629 — — 106,629 Convertible notes receivable 2,767 — — 2,767 $ 109,700 $ — $ 304 $ 109,396 Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 1,286 $ — $ 1,286 $ — Derivative liabilities - freestanding instruments (FX) 427 — 427 — Derivative liabilities - embedded exchange feature 181,700 — — 181,700 Contingent consideration arrangements 98,382 — — 98,382 $ 281,795 $ — $ 1,713 $ 280,082
Reconciliation of Beginning and Ending Balances of Recurring Fair Value Measurements	The following table provides a reconciliation of the beginning and ending balances of our recurring fair value measurements, using significant unobservable inputs (Level 3) (in thousands): Capped Call Derivative Asset Convertible Notes Receivable Embedded Exchange Feature Derivative Liability Contingent Consideration Liability Arrangements As of December 31, 2021 $ 106,629 $ 2,767 $ 181,700 $ 98,382 Additions — — — 26,369 Utilized as business combination consideration — (2,489) — — Changes in fair value (1) (45,021) — (47,610) (27,359) Total at June 30, 2022 61,608 278 134,090 97,392 Less current portion at June 30, 2022 — — — 5,552 Long-term portion at June 30, 2022 $ 61,608 $ 278 $ 134,090 $ 91,840 (1) The decrease in fair value associated with contingent consideration arrangements during the six months ended June 30, 2022 was primarily related to the change in discount rates due to increasing interest rates and the change in probability of the regulatory milestone-based payment associated with the acquisition of TandemLife.
Schedule of Fair Value of Contingent Consideration Arrangements by Acquisition	The following table provides the fair value of our Level 3 contingent consideration arrangements by acquisition (in thousands): June 30, 2022 December 31, 2021 ImThera $ 70,283 $ 86,830 ALung 21,557 — TandemLife 5,552 11,552 $ 97,392 $ 98,382
Significant Unobservable Inputs Related to Contingent Consideration	The sales-based earnout was valued using projected sales from our internal strategic plan and is a Level 3 fair value measurement, which includes the following significant unobservable inputs (in thousands): ALung Acquisition Fair value at May 2, 2022 Valuation Technique Unobservable Input Ranges Sales-based earnout $ 26,369 Monte Carlo simulation Risk-adjusted discount rate 9.7% - 11.1% Credit risk discount rate 6.4% - 8.0% Revenue volatility 38.5% Projected years of earnout 2023 - 2027 ImThera Acquisition Valuation Technique Unobservable Input Inputs Regulatory milestone-based payment Discounted cash flow Discount rate 11.8% Probability of payment 85% Projected payment year 2024 Sales-based earnout Monte Carlo simulation Risk-adjusted discount rate 14.4% Credit risk discount rate 12.4% - 13.4% Revenue volatility 32.5% Probability of payment 85% Projected years of earnout 2025 - 2028 The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of June 30, 2022: TandemLife Acquisition Valuation Technique Unobservable Input Inputs Regulatory milestone-based payment Discounted cash flow Discount rate 10.1% Probability of payment 45% Projected payment year 2023 The ALung business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain sales-based thresholds associated with sales of products. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of June 30, 2022: ALung Acquisition Valuation Technique Unobservable Input Inputs Sales-based earnout Monte Carlo simulation Risk-adjusted discount rate 10.4% - 11.2% Credit risk discount rate 11.0% - 13.2% Revenue volatility 37.5% Projected years of earnout 2023 - 2027

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The outstanding principal amount of our long-term debt as of June 30, 2022 and December 31, 2021 was as follows (in thousands, except interest rates): June 30, 2022 December 31, 2021 Maturity Interest Rate 2020 Cash Exchangeable Senior Notes $ 232,081 $ 225,140 December 2025 3.00% Bridge Loan Facility 220,000 — N/A 5.83% Bank of America Merrill Lynch Banco Múltiplo S.A. 6,499 6,113 July 2023 11.46% Mediocredito Italiano 2,332 3,379 December 2023 0.50% - 2.74% Bank of America, U.S. 1,500 1,500 January 2023 5.45% Other 585 663 Total long-term facilities 462,997 236,795 Less current portion of long-term debt 3,205 226,946 Total long-term debt $ 459,792 $ 9,849

Derivatives and Risk Manageme_2

Derivatives and Risk Management (Tables)	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Derivative Contracts Designated Cash Flow Hedges	The gross notional amounts of open derivative contracts designated as cash flow hedges at June 30, 2022 and December 31, 2021 were as follows (in thousands): Description of Derivative Contract June 30, 2022 December 31, 2021 FX derivative contracts to be exchanged for British Pounds $ 5,416 $ 11,160 FX derivative contracts to be exchanged for Japanese Yen 3,334 6,648 FX derivative contracts to be exchanged for Euros 29,110 58,224 $ 37,860 $ 76,032
Schedule of Cash Flow Hedges Included in AOCI	After-tax net gain associated with derivatives designated as cash flow hedges recorded in the ending balance of AOCI and the amount expected to be reclassified to earnings in the next 12 months are as follows (in thousands): Description of Derivative Contract After-Tax Net Loss in AOCI as of June 30, 2022 After-Tax Net Loss in AOCI as of June 30, 2022 Expected to be Reclassified to Earnings in Next 12 Months FX derivative contracts $ (2,869) $ (2,869) Pre-tax gains (losses) for derivative contracts designated as cash flow hedges recognized in other comprehensive income (loss) (“OCI”) and the amount reclassified to earnings from AOCI were as follows (in thousands): Three Months Ended June 30, 2022 2021 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI Gains (Losses) Reclassified from AOCI to Earnings Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other income/(expense) $ (1,116) $ 1,238 $ (621) $ (1,306) FX derivative contracts SG&A — (1,122) — 858 $ (1,116) $ 116 $ (621) $ (448) Six Months Ended June 30, 2022 2021 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings Losses Recognized in OCI Losses Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ (1,758) $ 1,679 $ (2,844) $ (2,802) FX derivative contracts SG&A — (1,510) — 1,543 $ (1,758) $ 169 $ (2,844) $ (1,259)
Schedule of Fair Value of Derivative Instruments in Statement of Financial Position	The following tables present the fair value and the location of derivative contracts reported on the condensed consolidated balance sheets (in thousands): June 30, 2022 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) FX derivative contracts Current derivative assets $ 585 Current derivative liabilities $ 3,386 Total derivatives designated as hedging instruments 585 3,386 Derivatives Not Designated as Hedging Instruments FX derivative contracts Current derivative assets 1,935 Current derivative liabilities 3 FX derivative contracts Current derivative liabilities 157 Capped call derivatives Long-term derivative assets 61,608 Embedded exchange feature Long-term derivative liabilities 134,090 Total derivatives not designated as hedging instruments 63,700 134,093 Total derivatives $ 64,285 $ 137,479 December 31, 2021 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) FX derivative contracts Current derivative liabilities $ 243 Current derivative liabilities $ 1,286 Total derivatives designated as hedging instruments 243 1,286 Derivatives Not Designated as Hedging Instruments FX derivative contracts Current derivative liabilities 61 Current derivative liabilities 427 Capped call derivatives Current derivative assets 106,629 Embedded exchange feature Current derivative liabilities 181,700 Total derivatives not designated as hedging instruments 106,690 182,127 Total derivatives $ 106,933 $ 183,413 (1) For the classification of inputs used to evaluate the fair value of our derivatives, refer to “Note 5. Fair Value Measurements.”

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Litigation Provision Liabilities	Changes in the carrying amount of the litigation provision liability are as follows (in thousands): Total litigation provision liability at December 31, 2021 $ 39,470 Payments (2,773) Adjustments (1) 709 FX and other (517) Total litigation provision liability at June 30, 2022 36,889 Less current portion of litigation provision liability at June 30, 2022 30,960 Long-term portion of litigation provision liability at June 30, 2022 (2) $ 5,929 (1) Adjustments to the litigation provision are included within other operating expenses on the condensed consolidated statements of income (loss). (2) Included within other long-term liabilities on the condensed consolidated balance sheet.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity	The tables below present the condensed consolidated statements of stockholders’ equity as of and for the three and six months ended June 30, 2022 and 2021 (in thousands): Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Accumulated Deficit (1) Total Stockholders' Equity (1) March 31, 2022 53,764 $ 82,298 $ 2,121,098 $ (619) $ (16,132) $ (894,791) $ 1,291,854 Stock-based compensation plans 46 61 12,160 222 — — 12,443 Net income — — — — — 16,444 16,444 Other comprehensive loss — — — — (38,738) — (38,738) June 30, 2022 53,810 $ 82,359 $ 2,133,258 $ (397) $ (54,870) $ (878,347) $ 1,282,003 March 31, 2021 49,455 $ 76,310 $ 1,770,407 $ (798) $ 1,938 $ (792,727) $ 1,055,130 Stock-based compensation plans 68 95 8,706 93 — — 8,894 Net loss — — — — — (56,487) (56,487) Other comprehensive income — — — — 21,137 — 21,137 June 30, 2021 49,523 $ 76,405 $ 1,779,113 $ (705) $ 23,075 $ (849,214) $ 1,028,674 Ordinary Shares Ordinary Shares - Amount Additional Paid-In Capital Treasury Stock Accumulated Other Comprehensive (Loss) Income Accumulated Deficit (1) Total Stockholders' Equity (1) December 31, 2021 53,762 $ 82,295 $ 2,117,961 $ (650) $ (7,177) $ (897,784) $ 1,294,645 Stock-based compensation plans 48 64 15,297 253 — — 15,614 Net income — — — — — 19,437 19,437 Other comprehensive loss — — — — (47,693) — (47,693) June 30, 2022 53,810 $ 82,359 $ 2,133,258 $ (397) $ (54,870) $ (878,347) $ 1,282,003 December 30, 2020 49,447 $ 76,300 $ 1,768,156 $ (1,034) $ 27,809 $ (761,966) $ 1,109,265 Stock-based compensation plans 76 105 10,957 329 — — 11,391 Net loss — — — — — (87,248) (87,248) Other comprehensive loss — — — — (4,734) — (4,734) June 30, 2021 49,523 $ 76,405 $ 1,779,113 $ (705) $ 23,075 $ (849,214) $ 1,028,674 (1) Accumulated deficit and total stockholders’ equity as of June 30, 2021 and net loss for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”
Schedule of Accumulated Other Comprehensive Income (Loss)	The table below presents the change in each component of AOCI, net of tax, and the reclassifications out of AOCI into net income for the six months ended June 30, 2022 and 2021 (in thousands): Change in Unrealized Gain (Loss) on Derivatives Foreign Currency Translation Adjustments Gain (Loss) (1) Total December 31, 2021 $ (945) $ (6,232) $ (7,177) Other comprehensive loss before reclassifications, before tax (1,758) (45,766) (47,524) Tax benefit — — — Other comprehensive loss before reclassifications, net of tax (1,758) (45,766) (47,524) Reclassification of gain from accumulated other comprehensive loss, before tax (169) — (169) Reclassification of tax benefit — — — Reclassification of gain from accumulated other comprehensive loss, after tax (169) — (169) Net current-period other comprehensive loss, net of tax (1,927) (45,766) (47,693) June 30, 2022 $ (2,872) $ (51,998) $ (54,870) December 31, 2020 $ 2,319 $ 25,490 $ 27,809 Other comprehensive loss before reclassifications, before tax (2,844) (3,530) (6,374) Tax benefit 683 — 683 Other comprehensive loss before reclassifications, net of tax (2,161) (3,530) (5,691) Reclassification of loss from accumulated other comprehensive income, before tax 1,259 — 1,259 Reclassification of tax benefit (302) — (302) Reclassification of loss from accumulated other comprehensive income, after tax 957 — 957 Net current-period other comprehensive loss, net of tax (1,204) (3,530) (4,734) June 30, 2021 $ 1,115 $ 21,960 $ 23,075 (1) Taxes are not provided for foreign currency translation adjustments as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned.

Stock-Based Incentive Plans (Ta

Stock-Based Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Incentive Plans	Stock-based incentive plans compensation expense is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Service-based restricted stock units (“RSUs”) $ 5,882 $ 5,205 $ 11,226 $ 10,047 Service-based stock appreciation rights (“SARs”) 3,720 3,064 6,658 6,386 Market performance-based restricted stock units 1,003 898 1,854 1,661 Operating performance-based restricted stock units 611 239 1,396 506 Employee share purchase plan 293 510 631 852 Total stock-based compensation expense $ 11,509 $ 9,916 $ 21,765 $ 19,452 Stock-based compensation agreements issued during the six months ended June 30, 2022, representing potential shares and their weighted average grant date fair values by type follows (shares in thousands, fair value in dollars): Six Months Ended June 30, 2022 Shares Weighted Average Grant Date Fair Value Service-based SARs 553,050 $ 34.13 Service-based RSUs 291,330 $ 79.04 Market performance-based RSUs 44,180 $ 103.02 Operating performance-based RSUs 44,174 $ 82.04

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Weighted-Average Shares Outstanding	Reconciliation of the shares used in the basic and diluted earnings per share computations for the three and six months ended June 30, 2022 and 2021 are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Basic weighted average shares outstanding 53,506 48,928 53,420 48,833 Add effects of share-based compensation instruments (1) 574 — 724 — Diluted weighted average shares outstanding 54,080 48,928 54,144 48,833 (1) Excluded from the computation of diluted earnings per share were stock options, SARs and restricted share units totaling 2.2 million and 3.9 million for the three months ended June 30, 2022 and 2021, respectively, and 2.2 and 4.1 million for the six months ended June 30, 2022 and 2021, respectively, because to include them would have been anti-dilutive under the treasury stock method.

Geographic and Segment Inform_2

Geographic and Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas	The table below presents net sales by operating segment and geographic region (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cardiopulmonary United States $ 37,865 $ 37,388 $ 75,961 $ 73,147 Europe 33,159 35,133 65,226 65,759 Rest of World 54,796 45,355 101,708 87,689 125,820 117,876 242,895 226,595 Neuromodulation United States 91,431 91,779 178,641 174,079 Europe 13,710 14,604 26,166 26,283 Rest of World 12,654 11,253 23,215 20,973 117,795 117,636 228,022 221,335 Advanced Circulatory Support United States 8,790 12,964 19,753 25,524 Europe 503 178 1,106 406 Rest of World 59 133 176 337 9,352 13,275 21,035 26,267 Other (1) United States — 2,212 — 4,929 Europe — 6,123 — 14,407 Rest of World 1,184 7,361 2,374 18,553 1,184 15,696 2,374 37,889 Totals United States 138,086 144,343 274,355 277,679 Europe (2) 47,372 56,038 92,498 106,855 Rest of World 68,693 64,102 127,473 127,552 Total (3) $ 254,151 $ 264,483 $ 494,326 $ 512,086 (1) For 2021, other primarily includes the net sales of the Company’s Heart Valves business, which was disposed of on June 1, 2021. (2) Europe includes those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in Rest of World.
Schedule of Segment Reporting Information, by Segment	The table below presents a reconciliation of segment income (loss) to consolidated income (loss) before tax (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 (1) 2022 2021 (1) Cardiopulmonary $ 3,644 $ (25,099) $ 10,539 $ (23,657) Neuromodulation 51,360 38,156 88,838 72,239 Advanced Circulatory Support 3,485 (1,311) (1,953) 1,082 Other (2) (19,450) (37,634) (42,532) (67,829) Total reportable segment income (loss) 39,039 (25,888) 54,892 (18,165) Other expenses (3) 7,283 10,374 13,631 23,795 Operating income (loss) 31,756 (36,262) 41,261 (41,960) Interest expense (14,388) (16,515) (22,228) (32,451) Foreign exchange and other income/(expense) 1,633 239 5,537 (6,204) Income (loss) before tax $ 19,001 $ (52,538) $ 24,570 $ (80,615) (1) Segment income for the three and six months ended June 30, 2021 has been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.” (2) Other includes corporate shared service expenses for finance, legal, human resources, information technology and corporate business development. For 2021, other also includes the results of the Company’s Heart Valves business, which was disposed of on June 1, 2021. (3) Other expenses primarily consist of amortization of intangible assets, merger and integration expense and restructuring expense. Assets by segment are as follows (in thousands): June 30, 2022 December 31, 2021 Cardiopulmonary $ 860,410 $ 921,481 Neuromodulation 651,085 646,394 Advanced Circulatory Support 259,515 231,846 Other 565,235 401,230 Total $ 2,336,245 $ 2,200,951 Capital expenditures by segment are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cardiopulmonary $ 3,213 $ 2,671 $ 5,042 $ 5,720 Neuromodulation 46 51 130 91 Advanced Circulatory Support — 528 684 1,084 Other 2,604 2,882 5,587 4,351 Total $ 5,863 $ 6,132 $ 11,443 $ 11,246
Schedule of Goodwill by Segment	The changes in the carrying amount of goodwill by segment for the six months ended June 30, 2022 were as follows (in thousands): Cardiopulmonary Neuromodulation Advanced Circulatory Support Total December 31, 2021 $ 398,245 $ 398,754 $ 102,526 $ 899,525 Goodwill as a result of acquisition — — 25,893 25,893 Foreign currency adjustments (27,348) — — (27,348) June 30, 2022 $ 370,897 $ 398,754 $ 128,419 $ 898,070
Long-lived Assets by Geographic Areas	Property, plant and equipment, net by geography are as follows (in thousands): June 30, 2022 December 31, 2021 United States $ 62,704 $ 60,852 Europe 76,309 85,313 Rest of World 4,299 3,901 Total $ 143,312 $ 150,066

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	6 Months Ended
	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Inventories	Inventories consisted of the following (in thousands): June 30, 2022 December 31, 2021 Raw materials $ 53,019 $ 43,958 Work-in-process 18,227 14,161 Finished goods 48,169 47,721 $ 119,415 $ 105,840
Accrued Liabilities	Accrued liabilities and other consisted of the following (in thousands): June 30, 2022 December 31, 2021 Operating lease liabilities $ 10,245 $ 11,261 Contract liabilities 9,097 8,419 Amount payable to Gyrus Capital S.A. 8,767 11,418 Legal and other administrative costs 8,524 8,948 Research and development costs 6,065 5,329 Contingent consideration (1) 5,552 11,552 Provisions for agents, returns and other 1,700 2,535 Other accrued expenses 34,002 29,475 $ 83,952 $ 88,937 (1) Refer to “Note 5. Fair Value Measurements”
Foreign Exchange and Other Gains (Losses)	The table below presents the items included within “Foreign exchange and other income/(expense)” on the condensed consolidated statements of income (loss) (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Exchangeable Notes fair value adjustment (1) $ 36,570 $ (26,048) $ 47,610 $ (52,384) Capped call fair value adjustment (1) (35,109) 19,408 (45,021) 31,957 Investment revaluation (2) — — — 4,640 Dividend Income (2) — 3,133 — 3,133 Other derivative liabilities fair value adjustment — 923 — 4,090 Foreign exchange rate fluctuations 341 1,544 3,132 1,134 Interest income 57 189 77 115 Other (226) 1,090 (261) 1,111 Foreign exchange and other income/(expense) $ 1,633 $ 239 $ 5,537 $ (6,204) (1) Refer to “Note 5. Fair Value Measurements” (2) Refer to “Note 4. Investments”
Schedule of Cash, Cash Equivalents and Restricted Cash	The table below presents a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the amounts shown on the condensed consolidated statement of cash flows (in thousands): June 30, 2022 December 31, 2021 Cash and cash equivalents $ 109,022 $ 207,992 Restricted cash (1) 297,747 — Cash, cash equivalents and restricted cash $ 406,769 $ 207,992 (1) Restricted cash represents funds held as collateral for the SNIA Litigation Guarantee. Refer to “Note 8. Commitments and Contingencies.”
Schedule of Cash, Cash Equivalents and Restricted Cash	The table below presents a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the amounts shown on the condensed consolidated statement of cash flows (in thousands): June 30, 2022 December 31, 2021 Cash and cash equivalents $ 109,022 $ 207,992 Restricted cash (1) 297,747 — Cash, cash equivalents and restricted cash $ 406,769 $ 207,992 (1) Restricted cash represents funds held as collateral for the SNIA Litigation Guarantee. Refer to “Note 8. Commitments and Contingencies.”

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Financial Statements - Narrative (Details) $ in Thousands, € in Millions		6 Months Ended	12 Months Ended
	Feb. 21, 2022 EUR (€)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 18, 2022
Segment Reporting Information [Line Items]
Restricted cash		$ 297,747	$ 0
Revenue Benchmark | Geographic Concentration Risk | Russian Federation
Segment Reporting Information [Line Items]
Concentration risk, percentage			1%
Bridge Loan
Segment Reporting Information [Line Items]
Restricted cash		297,700
SNIA | Judicial Ruling | Bridge Loan
Segment Reporting Information [Line Items]
Percentage of cash collateral required as guarantee				105%
SNIA | Judicial Ruling | Surety Bond
Segment Reporting Information [Line Items]
First demand bank guarantee	€ 270	$ 281,200

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Financial Statements - Consolidated Statements of Income (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales	$ 69,801	$ 92,204	[1]	$ 141,533	$ 176,399	[1]
Operating loss	31,756	(36,262)	[1]	41,261	(41,960)	[1]
Income (loss) before tax	19,001	(52,538)	[1]	24,570	(80,615)	[1]
Income tax expense	2,515	3,908	[1]	5,052	6,552	[1]
Net income (loss)	$ 16,444	$ (56,487)	[1],[2]	$ 19,437	$ (87,248)	[1],[2],[3]
Basic loss per share (in dollars per share)	$ 0.31	$ (1.15)	[1]	$ 0.36	$ (1.79)	[1]
Diluted loss per share (in dollars per share)	$ 0.30	$ (1.15)	[1]	$ 0.36	$ (1.79)	[1]
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales		$ 90,803			$ 173,723
Operating loss		(34,861)			(39,284)
Income (loss) before tax		(51,137)			(77,939)
Income tax expense		4,140			6,996
Net income (loss)		$ (55,318)			$ (85,016)
Basic loss per share (in dollars per share)		$ (1.13)			$ (1.74)
Diluted loss per share (in dollars per share)		$ (1.13)			$ (1.74)
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales		$ 1,401			$ 2,676
Operating loss		(1,401)			(2,676)
Income (loss) before tax		(1,401)			(2,676)
Income tax expense		(232)			(444)
Net income (loss)		$ (1,169)			$ (2,232)
Basic loss per share (in dollars per share)		$ (0.02)			$ (0.05)
Diluted loss per share (in dollars per share)		$ (0.02)			$ (0.05)
As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales		$ 92,204			$ 176,399
Operating loss		(36,262)			(41,960)
Income (loss) before tax		(52,538)			(80,615)
Income tax expense		3,908			6,552
Net income (loss)		$ (56,487)			$ (87,248)
Basic loss per share (in dollars per share)		$ (1.15)			$ (1.79)
Diluted loss per share (in dollars per share)		$ (1.15)			$ (1.79)
[1]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[2]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[3]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Financial Statements - Consolidated Statements of Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	$ 16,444	$ (56,487)	[1],[2]	$ 19,437	$ (87,248)	[1],[2],[3]
Total comprehensive loss	$ (22,294)	(35,350)	[1]	$ (28,256)	(91,982)	[1]
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(55,318)			(85,016)
Total comprehensive loss		(34,181)			(89,750)
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(1,169)			(2,232)
Total comprehensive loss		(1,169)			(2,232)
As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(56,487)			(87,248)
Total comprehensive loss		$ (35,350)			$ (91,982)
[1]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[2]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[3]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Unaudited Condensed Consolida_7

Unaudited Condensed Consolidated Financial Statements - Consolidated Statements of Stockholders' Equity (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Stockholders’ Equity	$ 1,282,003	$ 1,291,854	$ 1,294,645	$ 1,028,674	$ 1,055,130	$ 1,109,265
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Stockholders’ Equity				1,040,470
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Stockholders’ Equity				(11,796)
Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Stockholders’ Equity	$ (878,347)	$ (894,791)	$ (897,784)	(849,214)	$ (792,727)	$ (761,966)
Accumulated Deficit | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Stockholders’ Equity				(837,418)
Accumulated Deficit | Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Stockholders’ Equity				$ (11,796)

Unaudited Condensed Consolida_8

Unaudited Condensed Consolidated Financial Statements - Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	$ 16,444	$ (56,487)	[1],[2]	$ 19,437	$ (87,248)	[1],[2],[3]
Deferred tax expense				645	913	[3]
Inventories				(16,461)	3,897	[3]
Net cash used in operating activities				15,580	45,111	[3]
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(55,318)			(85,016)
Deferred tax expense					1,357
Inventories					1,221
Net cash used in operating activities					45,111
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(1,169)			(2,232)
Deferred tax expense				$ (444)
Inventories					2,676
Net cash used in operating activities					0
As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		$ (56,487)			(87,248)
Deferred tax expense					913
Inventories					3,897
Net cash used in operating activities					$ 45,111
[1]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[2]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[3]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Business Combinations - Narrati

Business Combinations - Narrative (Details) - ALung Acquisition - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	May 02, 2022	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Agreement to acquire equity interests	97%
Maximum consideration	$ 110,000
Cash to be paid at closing	10,000		$ 15,586
Contingent consideration	$ 100,000
Legal and valuation expense		$ 4,400	$ 4,400
ALung Acquisition
Business Acquisition [Line Items]
Ownership percentage				3%

Business Combinations - Fair Va

Business Combinations - Fair Value of Consideration Transferred (Details) - ALung Acquisition - USD ($) $ in Thousands		6 Months Ended
	May 02, 2022	Jun. 30, 2022
Business Acquisition [Line Items]
Cash and other considerations	$ 10,000	$ 15,586
Contingent consideration		26,369
Fair value of consideration transferred		$ 41,955

Business Combinations - Purchas

Business Combinations - Purchase Price Allocation (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 898,070	$ 899,525
ALung Acquisition
Business Acquisition [Line Items]
Developed technology - 15-year life	13,950
Goodwill	25,893
Other assets and liabilities, net	2,112
Net assets acquired	$ 41,955
Useful life	15 years

Business Combinations - Sales-b

Business Combinations - Sales-based Earnout (Details) $ in Thousands	Jun. 30, 2022 USD ($)	May 02, 2022 USD ($)	Dec. 31, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value at May 2, 2022	$ 91,840		$ 86,830
Level 3 | ALung Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value at May 2, 2022		$ 26,369
Risk-adjusted discount rate | Level 3 | Minimum | ALung Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input		0.097
Risk-adjusted discount rate | Level 3 | Maximum | ALung Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input		0.111
Credit risk discount rate | Level 3 | Minimum | ALung Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input		0.064
Credit risk discount rate | Level 3 | Maximum | ALung Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input		0.080
Revenue volatility | Level 3 | ALung Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input		0.385

Divestiture of Heart Valve Bu_2

Divestiture of Heart Valve Business - Narrative (Details) - Heart Valves € in Millions, $ in Millions							1 Months Ended	3 Months Ended	6 Months Ended
	Dec. 30, 2022 EUR (€)	Jul. 29, 2022 EUR (€)	Jul. 29, 2022 USD ($)	Jun. 01, 2021 EUR (€)	Jun. 01, 2021 USD ($)	Apr. 09, 2021	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jul. 31, 2022 EUR (€)	Dec. 02, 2020 EUR (€)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sale | $								$ (0.1)	$ 0.8
Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payment for working capital and indebtedness adjustments | €										€ 4.8
Warranty, cap on claims | $			$ 8
Subsequent Event | Mitral
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Compensation sought		€ 20.8	$ 21.2
Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration | €											€ 60
Sale and purchase deferral period						2 years
Proceeds from sales of business, affiliate and productive assets				€ 34.8	$ 42.5
Business Combination, Consideration, Tranche One | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sales of business, affiliate and productive assets | $							$ 3
Forecast | Business Combination, Consideration, Tranche Two | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sales of business, affiliate and productive assets | €	€ 9.3

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Apr. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021		May 02, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Carrying value of investments		$ 14,000			$ 14,000				$ 16,600
Proceeds from sale of Respicardia investment and loan					0	$ 23,057	[1]
Gain (loss) on investment		$ 0	$ 0		$ 0	$ 4,640
ALung Acquisition
Schedule of Equity Method Investments [Line Items]
Agreement to acquire equity interests								97%
A Lung Technologies Inc | Convertible Notes Receivable
Schedule of Equity Method Investments [Line Items]
Carrying value of note receivable									2,500
MD Start II
Schedule of Equity Method Investments [Line Items]
Dividends			$ 3,100
ALung Acquisition
Schedule of Equity Method Investments [Line Items]
Investments									$ 3,000
ALung Acquisition | ALung Acquisition
Schedule of Equity Method Investments [Line Items]
Ownership percentage									3%
Cost Method Investee | Zoll Medical Corporation
Schedule of Equity Method Investments [Line Items]
Proceeds from sale of Respicardia investment and loan	$ 23,100
Gain (loss) on investment				$ 4,600
Cost Method Investee | Prepaid Expenses and Other Current Assets | Zoll Medical Corporation
Schedule of Equity Method Investments [Line Items]
Carrying value of investments										$ 17,700
Outstanding loans										$ 800
[1]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Liabilities:
Contingent consideration	$ 91,840	$ 86,830
Capped Call Derivatives
Assets:
Derivative asset	61,600
Fair Value, Recurring
Assets:
Convertible notes receivable	278	2,767
Total assets	64,563	109,700
Liabilities:
Contingent consideration	97,392	98,382
Total liabilities	234,871	281,795
Fair Value, Recurring | Embedded Exchange Feature
Liabilities:
Derivative liabilities	134,090	181,700
Fair Value, Recurring | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	585	243
Liabilities:
Derivative liabilities	3,386	1,286
Fair Value, Recurring | Derivatives Not Designated as Hedging Instruments | Freestanding Instrument
Assets:
Derivative asset	2,092	61
Liabilities:
Derivative liabilities	3	427
Fair Value, Recurring | Derivatives Not Designated as Hedging Instruments | Capped Call Derivatives
Assets:
Derivative asset	61,608	106,629
Fair Value, Recurring | Level 1
Assets:
Convertible notes receivable	0	0
Total assets	0	0
Liabilities:
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring | Level 1 | Embedded Exchange Feature
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 1 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	0	0
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 1 | Derivatives Not Designated as Hedging Instruments | Freestanding Instrument
Assets:
Derivative asset	0	0
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 1 | Derivatives Not Designated as Hedging Instruments | Capped Call Derivatives
Assets:
Derivative asset	0	0
Fair Value, Recurring | Level 2
Assets:
Convertible notes receivable	0	0
Total assets	2,677	304
Liabilities:
Contingent consideration	0	0
Total liabilities	3,389	1,713
Fair Value, Recurring | Level 2 | Embedded Exchange Feature
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 2 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	585	243
Liabilities:
Derivative liabilities	3,386	1,286
Fair Value, Recurring | Level 2 | Derivatives Not Designated as Hedging Instruments | Freestanding Instrument
Assets:
Derivative asset	2,092	61
Liabilities:
Derivative liabilities	3	427
Fair Value, Recurring | Level 2 | Derivatives Not Designated as Hedging Instruments | Capped Call Derivatives
Assets:
Derivative asset	0	0
Fair Value, Recurring | Level 3
Assets:
Convertible notes receivable	278	2,767
Total assets	61,886	109,396
Liabilities:
Contingent consideration	97,392	98,382
Total liabilities	231,482	280,082
Fair Value, Recurring | Level 3 | Embedded Exchange Feature
Liabilities:
Derivative liabilities	134,090	181,700
Fair Value, Recurring | Level 3 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative asset	0	0
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 3 | Derivatives Not Designated as Hedging Instruments | Freestanding Instrument
Assets:
Derivative asset	0	0
Liabilities:
Derivative liabilities	0	0
Fair Value, Recurring | Level 3 | Derivatives Not Designated as Hedging Instruments | Capped Call Derivatives
Assets:
Derivative asset	$ 61,608	$ 106,629

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Recurring Fair Value Measurements (Details) - Fair Value, Recurring - Level 3 - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022
Liabilities Measured on Recurring Basis
Total at beginning period	$ 98,382
Total at period end	97,392
Embedded Exchange Feature Derivative Liability
Liabilities Measured on Recurring Basis
Total at beginning period	181,700
Additions	0
Payment	0
Changes in fair value (1)	(47,610)
Total at period end	134,090
Less current portion at period end	0
Long-term portion at period end	134,090
Contingent Consideration Liability Arrangements
Liabilities Measured on Recurring Basis
Total at beginning period	98,382
Additions	26,369
Payment	0
Changes in fair value (1)	(27,359)
Total at period end	97,392
Less current portion at period end	5,552
Long-term portion at period end	91,840
Capped Call Derivative Asset
Assets Measured on Recurring Basis
As of beginning period	106,629
Additions	0
Utilized as business combination consideration	0
Changes in fair value (1)	(45,021)
Total at period end	61,608
Less current portion at period end	0
Long-term portion at period end	61,608
Convertible Notes Receivable
Assets Measured on Recurring Basis
As of beginning period	2,767
Additions	0
Utilized as business combination consideration	(2,489)
Changes in fair value (1)	0
Total at period end	278
Less current portion at period end	0
Long-term portion at period end	$ 278

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	Jun. 30, 2022 USD ($)	Jun. 30, 2020 USD ($)	Jun. 17, 2020 USD ($)
Embedded Exchange Feature
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
10 percent decrease in stock price volatility, fair value	$ 118,500,000
10 percent increase in stock price volatility, fair value	146,800,000
Capped Call Derivatives
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset	61,600,000
10 percent decrease in stock price volatility, fair value	65,000,000
10 percent increase in stock price volatility, fair value	$ 57,400,000
Measurement Input, Stock Price Volatility | Embedded Exchange Feature
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.54
Measurement Input, Stock Price Volatility | Capped Call Derivatives
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.54
Senior Notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, face amount			$ 287,500,000
Fair value of embedded derivative liability	$ 134,100,000
2020 Cash Exchangeable Senior Notes | Senior Notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, face amount		$ 287,500,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Contingent Consideration by Acquisition (Details) - USD ($) $ in Thousands	Jun. 30, 2022	May 02, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	$ 91,840		$ 86,830
Fair Value, Recurring
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	97,392		98,382
Fair Value, Recurring | Level 3
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	97,392		98,382
Total fair value of Level 3 contingent consideration arrangements	97,392		98,382
ImThera | Fair Value, Recurring | Level 3
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	70,283		86,830
ALung Acquisition | Level 3
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration		$ 26,369
ALung Acquisition | Fair Value, Recurring | Level 3
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	21,557		0
TandemLife | Fair Value, Recurring | Level 3
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	$ 5,552		$ 11,552

Fair Value Measurements - Signi

Fair Value Measurements - Significant Unobservable Inputs (Details) - Level 3	Jun. 30, 2022
ImThera | Discounted cash flow | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.118
ImThera | Discounted cash flow | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.85
ImThera | Monte Carlo simulation | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.85
ImThera | Monte Carlo simulation | Risk-adjusted discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.144
ImThera | Monte Carlo simulation | Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.325
ImThera | Minimum | Monte Carlo simulation | Credit risk discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.124
ImThera | Maximum | Monte Carlo simulation | Credit risk discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.134
TandemLife | Discounted cash flow | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.101
TandemLife | Discounted cash flow | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.45
ALung Acquisition | Monte Carlo simulation | Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.375
ALung Acquisition | Minimum | Monte Carlo simulation | Risk-adjusted discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.104
ALung Acquisition | Minimum | Monte Carlo simulation | Credit risk discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.110
ALung Acquisition | Maximum | Monte Carlo simulation | Risk-adjusted discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.112
ALung Acquisition | Maximum | Monte Carlo simulation | Credit risk discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.132

Financing Arrangements - Schedu

Financing Arrangements - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 17, 2020
Debt Instrument [Line Items]
Total long-term facilities	$ 462,997	$ 236,795
Less current portion of long-term debt	3,205	226,946
Long-term debt obligations	$ 459,792	9,849
Bank of America Merrill Lynch Banco Múltiplo S.A.
Debt Instrument [Line Items]
Interest rate, stated percentage	11.46%
Mediocredito Italiano | Minimum
Debt Instrument [Line Items]
Interest rate, stated percentage	0.50%
Mediocredito Italiano | Maximum
Debt Instrument [Line Items]
Interest rate, stated percentage	2.74%
Bank of America, U.S.
Debt Instrument [Line Items]
Interest rate, stated percentage	5.45%
Senior Notes
Debt Instrument [Line Items]
Total long-term facilities	$ 232,081	225,140
Interest rate, stated percentage	3%		3%
Bridge Loan
Debt Instrument [Line Items]
Total long-term facilities	$ 220,000	0
Interest rate, stated percentage	5.83%
Loans Payable | Bank of America Merrill Lynch Banco Múltiplo S.A.
Debt Instrument [Line Items]
Total long-term facilities	$ 6,499	6,113
Loans Payable | Mediocredito Italiano
Debt Instrument [Line Items]
Total long-term facilities	2,332	3,379
Loans Payable | Bank of America, U.S.
Debt Instrument [Line Items]
Total long-term facilities	1,500	1,500
Other
Debt Instrument [Line Items]
Total long-term facilities	$ 585	$ 663

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) $ / shares in Units, € in Millions			3 Months Ended	6 Months Ended
	Feb. 24, 2022 USD ($)	Jun. 17, 2020 USD ($)	Jun. 30, 2022 USD ($) claim $ / shares	Jun. 30, 2022 USD ($) claim $ / shares	Jun. 30, 2021 USD ($)		Jun. 30, 2022 £ / shares	Mar. 18, 2022	Mar. 16, 2022 USD ($)	Feb. 24, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Aug. 13, 2021 USD ($)
Debt Instrument [Line Items]
Restricted cash			$ 297,747,000	$ 297,747,000							$ 0
Amortization of debt issuance costs				11,721,000	$ 8,989,000	[1]
Proceeds from long-term debt obligations				$ 218,342,000	0	[1]
Capped Call Derivatives
Debt Instrument [Line Items]
Derivative, cap price per share | $ / shares			$ 100	$ 100
Derivative asset			$ 61,600,000	$ 61,600,000
Bridge Loan
Debt Instrument [Line Items]
Restricted cash			$ 297,700,000	$ 297,700,000
Interest rate, stated percentage			5.83%	5.83%
Bridge Loan | SNIA | Judicial Ruling
Debt Instrument [Line Items]
Percentage of cash collateral required as guarantee								105%
Senior Notes
Debt Instrument [Line Items]
Interest rate			9.95%	9.95%
Debt discounts and issuance costs		$ 82,000,000
Amortization of debt issuance costs				$ 3,500,000	$ 6,900,000
Unamortized discount (premium), net			$ 55,400,000	$ 55,400,000							62,400,000
Debt instrument, face amount		287,500,000
Debt issuance costs, net		$ 7,000,000
Interest rate, stated percentage		3%	3%	3%
Proceeds from long-term debt obligations		$ 278,000,000
Unamortized discount		$ 75,000,000
Redemption, threshold par value | £ / shares							£ 1
Redemption price, percentage of exchange price				130%
Conversion price (in dollars per share) | $ / shares			$ 79.27	$ 79.27
Redemption, threshold trading days | claim			20	20
Redemption, threshold consecutive trading days | claim			30	30
Option to exchange, price per share | $ / shares			$ 60.98	$ 60.98
Redemption price, percentage				100%
Fair value of embedded derivative liability			$ 134,100,000	$ 134,100,000
Conversion ratio			0.016398
Revolving Credit Facility
Debt Instrument [Line Items]
Short-term debt			$ 3,000,000	3,000,000							2,700,000
Line of credit, maximum borrowing capacity												$ 125,000,000
Borrowed funds			$ 0	$ 0							$ 0
Revolving Credit Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
LIBOR floor rate												0%
Revolving Credit Facility | Bridge Loan
Debt Instrument [Line Items]
Interest rate			11.04%	11.04%
Borrowed funds			$ 220,000,000	$ 220,000,000
Debt discounts and issuance costs	$ 4,500,000
Amortization of debt issuance costs			$ 3,600,000	$ 4,500,000
Revolving Credit Facility | Bridge Loan | Goldman Sachs Bank USA
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity									$ 220,000,000	€ 200
Revolving Credit Facility | Bridge Loan | Goldman Sachs Bank USA | Period One
Debt Instrument [Line Items]
Debt instrument, period of interest rate increase	15 days
Revolving Credit Facility | Bridge Loan | Goldman Sachs Bank USA | Period Two
Debt Instrument [Line Items]
Debt instrument, period of interest rate increase	90 days
Revolving Credit Facility | Bridge Loan | Goldman Sachs Bank USA | Period Three
Debt Instrument [Line Items]
Debt instrument, period of interest rate increase	90 days
Revolving Credit Facility | Bridge Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
LIBOR floor rate									0.50%
Revolving Credit Facility | Bridge Loan | Euro Interbank Offered Rate (EURIBOR)
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	3.50%
Debt instrument, maximum interest rate	5.25%
Revolving Credit Facility | Bridge Loan | Euro Interbank Offered Rate (EURIBOR) | Period One
Debt Instrument [Line Items]
Debt instrument, increase in basis spread on variable rate	0.25%
Revolving Credit Facility | Bridge Loan | Euro Interbank Offered Rate (EURIBOR) | Period Two
Debt Instrument [Line Items]
Debt instrument, increase in basis spread on variable rate	0.50%
Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Interest rate			3.14%	3.14%
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Interest rate			11.63%	11.63%
Debt instrument, term				364 days
[1]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Derivatives and Risk Manageme_3

Derivatives and Risk Management - Narrative (Details) - Foreign Exchange Contract - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Foreign exchange and other income/(expense)
Derivative [Line Items]
Gain (loss) on derivative	$ 4	$ (1.7)	$ 5	$ 5.9
Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Notional amount	$ 117.2		$ 117.2		$ 136.7

Derivatives and Risk Manageme_4

Derivatives and Risk Management - Derivative Notional Amounts (Details) - Derivatives Designated as Hedging Instruments - Cash Flow Hedging - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Derivative [Line Items]
Notional amount	$ 37,860	$ 76,032
Foreign Exchange Contract | United Kingdom, Pounds
Derivative [Line Items]
Notional amount	5,416	11,160
Foreign Exchange Contract | Japan, Yen
Derivative [Line Items]
Notional amount	3,334	6,648
Foreign Exchange Contract | Euro Member Countries, Euro
Derivative [Line Items]
Notional amount	$ 29,110	$ 58,224

Derivatives and Risk Manageme_5

Derivatives and Risk Management - Amount of Gain (Loss) Recognized in OCI and Income Statement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Gains (Losses) Recognized in OCI	$ (1,116)	$ (621)	$ (1,758)	$ (2,844)
Gains (Losses) Reclassified from AOCI to Earnings	116	(448)	169	(1,259)
Cash Flow Hedging | Foreign Exchange Contract | Foreign exchange and other income/(expense)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (Losses) Recognized in OCI	(1,116)	(621)	(1,758)	(2,844)
Gains (Losses) Reclassified from AOCI to Earnings	1,238	(1,306)	1,679	(2,802)
Cash Flow Hedging | Foreign Exchange Contract | SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Gains (Losses) Recognized in OCI	0	0	0	0
Gains (Losses) Reclassified from AOCI to Earnings	$ (1,122)	$ 858	(1,510)	$ 1,543
Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
After-tax Net Loss in AOCI as of period end			(2,869)
After-Tax Net Loss in AOCI as of June 30, 2022 Expected to be Reclassified to Earnings in Next 12 Months			$ (2,869)

Derivatives and Risk Manageme_6

Derivatives and Risk Management - Fair Value of Derivative Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Total asset derivatives	$ 64,285	$ 106,933
Total liability derivatives	137,479	183,413
Derivatives Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Total asset derivatives	585	243
Total liability derivatives	3,386	1,286
Derivatives Designated as Hedging Instruments | Current derivative assets | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives	585
Derivatives Designated as Hedging Instruments | Current derivative liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives		243
Total liability derivatives	3,386	1,286
Derivatives Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Total asset derivatives	63,700	106,690
Total liability derivatives	134,093	182,127
Derivatives Not Designated as Hedging Instruments | Current derivative assets | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives	1,935
Derivatives Not Designated as Hedging Instruments | Current derivative assets | Capped Call Derivatives
Derivatives, Fair Value [Line Items]
Total asset derivatives		106,629
Derivatives Not Designated as Hedging Instruments | Current derivative liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives	157	61
Total liability derivatives	3	427
Derivatives Not Designated as Hedging Instruments | Current derivative liabilities | Embedded Exchange Feature
Derivatives, Fair Value [Line Items]
Total liability derivatives		$ 181,700
Derivatives Not Designated as Hedging Instruments | Long-term derivative assets | Capped Call Derivatives
Derivatives, Fair Value [Line Items]
Total asset derivatives	61,608
Derivatives Not Designated as Hedging Instruments | Long-term derivative liabilities | Embedded Exchange Feature
Derivatives, Fair Value [Line Items]
Total liability derivatives	$ 134,090

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) € in Thousands, $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Aug. 03, 2022 claim

Feb. 21, 2022 EUR (€)

Mar. 29, 2019 USD ($)

Apr. 01, 2016 EUR (€)

Jan. 31, 2021 EUR (€) repository_site

Jan. 31, 2020 USD ($)

Jul. 31, 2019 USD ($)

Mar. 31, 2022 USD ($)

Jun. 30, 2022 USD ($)

Dec. 31, 2021 USD ($)

Apr. 30, 2022 EUR (€)

Nov. 30, 2021 EUR (€)

Mar. 05, 2019 EUR (€)

Aug. 27, 2015 non-conformity

Other Commitments [Line Items]

Product remediation liability, net

$ 700

Reimbursed legal fees

€ 292

304,103

Environmental maintenance | €

€ 1,000

Subsequent Event

Other Commitments [Line Items]

Pending claims, number | claim

90

Number of settled claims | claim

6

Pending Litigation

Other Commitments [Line Items]

Estimate of possible loss

595,800

€ 572,100

Saluggia, Italy

Other Commitments [Line Items]

Number of national repository sites | repository_site

67

Estimated provision

35,900

Estimated liability

$ 39,300

Saluggia, Italy | Minimum

Other Commitments [Line Items]

Estimated provision

35,900

Saluggia, Italy | Maximum

Other Commitments [Line Items]

Estimated provision

$ 45,600

FDA Warning Letter

Other Commitments [Line Items]

Number of observed non-conformities | non-conformity

2

Product Liability

Other Commitments [Line Items]

Litigation settlement, amount awarded to other party

$ 225,000

Litigation provision liability

36,889

$ 39,470

First demand bank guarantee

2,773

Product Liability | First Payment

Other Commitments [Line Items]

Payments for legal settlements

$ 135,000

Product Liability | Second Payment

Other Commitments [Line Items]

Payments for legal settlements

$ 90,000

SNIA | Pending Litigation | SNIA s.p.a

Other Commitments [Line Items]

Compensation sought

4,000,000

Non-privileged creditor, amount | €

€ 454,000

SNIA | Judicial Ruling

Other Commitments [Line Items]

Estimate of possible loss

472,400

€ 453,600

SNIA | Judicial Ruling | Surety Bond

Other Commitments [Line Items]

First demand bank guarantee

€ 270,000

$ 281,200

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Product Liability (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Loss Contingency Accrual [Roll Forward]
Less current portion of litigation liability at period end	$ 30,960
Long-term portion of litigation provisions liability at period end	5,929
Product Liability
Loss Contingency Accrual [Roll Forward]
Total litigation provision liability at beginning of period	39,470
Payments	(2,773)
Adjustments	709
FX and other	(517)
Total litigation provision liability at end of period	$ 36,889

Stockholders' Equity - Statemen

Stockholders' Equity - Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)				53,761,510
Beginning balance	$ 1,291,854	$ 1,055,130		$ 1,294,645	$ 1,109,265
Stock-based compensation plans	12,443	8,894		15,614	11,391
Net income	16,444	(56,487)	[1],[2]	19,437	(87,248)	[1],[2],[3]
Other comprehensive income (loss)	$ (38,738)	21,137	[1]	$ (47,693)	(4,734)	[1]
Ending balance (in shares)	53,810,418			53,810,418
Ending balance	$ 1,282,003	$ 1,028,674		$ 1,282,003	$ 1,028,674
Ordinary Shares
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	53,764,000	49,455,000		53,762,000	49,447,000
Beginning balance	$ 82,298	$ 76,310		$ 82,295	$ 76,300
Stock-based compensation plans (in shares)	46,000	68,000		48,000	76,000
Stock-based compensation plans	$ 61	$ 95		$ 64	$ 105
Ending balance (in shares)	53,810,000	49,523,000		53,810,000	49,523,000
Ending balance	$ 82,359	$ 76,405		$ 82,359	$ 76,405
Additional Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	2,121,098	1,770,407		2,117,961	1,768,156
Stock-based compensation plans	12,160	8,706		15,297	10,957
Ending balance	2,133,258	1,779,113		2,133,258	1,779,113
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(619)	(798)		(650)	(1,034)
Stock-based compensation plans	222	93		253	329
Ending balance	(397)	(705)		(397)	(705)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(16,132)	1,938		(7,177)	27,809
Other comprehensive income (loss)	(38,738)	21,137		(47,693)	(4,734)
Ending balance	(54,870)	23,075		(54,870)	23,075
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(894,791)	(792,727)		(897,784)	(761,966)
Net income	16,444	(56,487)		19,437	(87,248)
Ending balance	$ (878,347)	$ (849,214)		$ (878,347)	$ (849,214)
[1]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[2]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”[3]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Stockholders' Equity - Comprehe

Stockholders' Equity - Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 1,291,854	$ 1,055,130		$ 1,294,645	$ 1,109,265
Other comprehensive loss before reclassifications, before tax				(47,524)	(6,374)
Tax benefit				0	683
Other comprehensive loss before reclassifications, net of tax				(47,524)	(5,691)
Reclassification of loss from accumulated other comprehensive income, before tax				(169)	1,259
Reclassification of tax benefit				0	(302)
Reclassification of gain from accumulated other comprehensive loss, after tax				(169)	957
Total other comprehensive (loss) income	(38,738)	21,137	[1]	(47,693)	(4,734)	[1]
Ending balance	1,282,003	1,028,674		1,282,003	1,028,674
Total
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(16,132)	1,938		(7,177)	27,809
Total other comprehensive (loss) income	(38,738)	21,137		(47,693)	(4,734)
Ending balance	(54,870)	23,075		(54,870)	23,075
Change in Unrealized Gain (Loss) on Derivatives
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance				(945)	2,319
Other comprehensive loss before reclassifications, before tax				(1,758)	(2,844)
Tax benefit				0	683
Other comprehensive loss before reclassifications, net of tax				(1,758)	(2,161)
Reclassification of loss from accumulated other comprehensive income, before tax				(169)	1,259
Reclassification of tax benefit				0	(302)
Reclassification of gain from accumulated other comprehensive loss, after tax				(169)	957
Total other comprehensive (loss) income				(1,927)	(1,204)
Ending balance	(2,872)	1,115		(2,872)	1,115
Foreign Currency Translation Adjustments Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance				(6,232)	25,490
Other comprehensive loss before reclassifications, before tax				(45,766)	(3,530)
Tax benefit				0	0
Other comprehensive loss before reclassifications, net of tax				(45,766)	(3,530)
Reclassification of loss from accumulated other comprehensive income, before tax				0	0
Reclassification of tax benefit				0	0
Reclassification of gain from accumulated other comprehensive loss, after tax				0	0
Total other comprehensive (loss) income				(45,766)	(3,530)
Ending balance	$ (51,998)	$ 21,960		$ (51,998)	$ 21,960
[1]The condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Stock-Based Incentive Plans - C

Stock-Based Incentive Plans - Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, compensation cost			$ 3,000
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, vesting period			4 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, vesting period			2 years
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, number of shares available for grant (in shares)	56,428		56,428
Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 11,509	$ 9,916	$ 21,765	$ 19,452
Service-based restricted stock units (“RSUs”) | Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	5,882	5,205	11,226	10,047
Service-based stock appreciation rights (“SARs”) | Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,720	3,064	$ 6,658	6,386
Market performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, vesting period			3 years
Market performance-based restricted stock units | Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,003	898	$ 1,854	1,661
Operating performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, vesting period			3 years
Operating performance-based restricted stock units | Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	611	239	$ 1,396	506
Employee share purchase plan | Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 293	$ 510	$ 631	$ 852
Employee share purchase plan | 2022 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, number of shares available for grant (in shares)	1,900,000		1,900,000
Other Awards | 2022 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, number of shares available for grant (in shares)	1,173,352		1,173,352

Stock-Based Incentive Plans - E

Stock-Based Incentive Plans - Executed Agreements (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Service-based stock appreciation rights (“SARs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	553,050
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 34.13
Service-based restricted stock units (“RSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	291,330
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 79.04
Market performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	44,180
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 103.02
Operating performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	44,174
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 82.04

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Effective tax rate (percent)	13.20%	(7.40%)	20.60%	(8.10%)
Unrecognized tax benefits	$ 1.6		$ 1.6		$ 1.7
Unrecognized tax benefits, potential decrease amount	$ 1		$ 1

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - shares shares in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Basic weighted average shares outstanding (in shares)	53,506	48,928	[1]	53,420	48,833	[1]
Add effects of share-based compensation instruments (in shares)	574	0		724	0
Diluted weighted average shares outstanding (in shares)	54,080	48,928	[1]	54,144	48,833	[1]
[1]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	2.2	3.9	2.2	4.1

Geographic and Segment Inform_3

Geographic and Segment Information - Segment Info (Details) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022 USD ($) geographic_region	Jun. 30, 2021 USD ($)		Jun. 30, 2022 USD ($) segment geographic_region	Jun. 30, 2021 USD ($)		Dec. 31, 2021 USD ($)
Segment Reporting Information [Line Items]
Reportable segments | segment				3
Number of geographic regions in which entity operates | geographic_region	3			3
Net sales	$ 254,151	$ 264,483	[1]	$ 494,326	$ 512,086	[1]
Operating income (loss)	31,756	(36,262)	[1]	41,261	(41,960)	[1]
Interest expense	(14,388)	(16,515)	[1]	(22,228)	(32,451)	[1]
Foreign exchange and other income/(expense)	1,633	239	[1]	5,537	(6,204)	[1]
Income (loss) before tax	19,001	(52,538)	[1]	24,570	(80,615)	[1]
Assets	2,336,245			2,336,245			$ 2,200,951
Operating Segments | Cardiopulmonary
Segment Reporting Information [Line Items]
Net sales	125,820	117,876		242,895	226,595
Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	117,795	117,636		228,022	221,335
Operating Segments | Advanced Circulatory Support
Segment Reporting Information [Line Items]
Net sales	9,352	13,275		21,035	26,267
Other
Segment Reporting Information [Line Items]
Net sales	1,184	15,696		2,374	37,889
Continuing Operations
Segment Reporting Information [Line Items]
Total reportable segment income (loss)	39,039	(25,888)		54,892	(18,165)
Other expenses	7,283	10,374		13,631	23,795
Operating income (loss)	31,756	(36,262)		41,261	(41,960)
Capital expenditures	5,863	6,132		11,443	11,246
Continuing Operations | Operating Segments | Cardiopulmonary
Segment Reporting Information [Line Items]
Total reportable segment income (loss)	3,644	(25,099)		10,539	(23,657)
Assets	860,410			860,410			921,481
Capital expenditures	3,213	2,671		5,042	5,720
Continuing Operations | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Total reportable segment income (loss)	51,360	38,156		88,838	72,239
Assets	651,085			651,085			646,394
Capital expenditures	46	51		130	91
Continuing Operations | Operating Segments | Advanced Circulatory Support
Segment Reporting Information [Line Items]
Total reportable segment income (loss)	3,485	(1,311)		(1,953)	1,082
Assets	259,515			259,515			231,846
Capital expenditures	0	528		684	1,084
Continuing Operations | Other
Segment Reporting Information [Line Items]
Total reportable segment income (loss)	(19,450)	(37,634)		(42,532)	(67,829)
Assets	565,235			565,235			$ 401,230
Capital expenditures	2,604	2,882		5,587	4,351
United States
Segment Reporting Information [Line Items]
Net sales	138,086	144,343		274,355	277,679
United States | Operating Segments | Cardiopulmonary
Segment Reporting Information [Line Items]
Net sales	37,865	37,388		75,961	73,147
United States | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	91,431	91,779		178,641	174,079
United States | Operating Segments | Advanced Circulatory Support
Segment Reporting Information [Line Items]
Net sales	8,790	12,964		19,753	25,524
United States | Other
Segment Reporting Information [Line Items]
Net sales	0	2,212		0	4,929
Europe
Segment Reporting Information [Line Items]
Net sales	47,372	56,038		92,498	106,855
Europe | Operating Segments | Cardiopulmonary
Segment Reporting Information [Line Items]
Net sales	33,159	35,133		65,226	65,759
Europe | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	13,710	14,604		26,166	26,283
Europe | Operating Segments | Advanced Circulatory Support
Segment Reporting Information [Line Items]
Net sales	503	178		1,106	406
Europe | Other
Segment Reporting Information [Line Items]
Net sales	0	6,123		0	14,407
Rest of World
Segment Reporting Information [Line Items]
Net sales	68,693	64,102		127,473	127,552
Rest of World | Operating Segments | Cardiopulmonary
Segment Reporting Information [Line Items]
Net sales	54,796	45,355		101,708	87,689
Rest of World | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	12,654	11,253		23,215	20,973
Rest of World | Operating Segments | Advanced Circulatory Support
Segment Reporting Information [Line Items]
Net sales	59	133		176	337
Rest of World | Other
Segment Reporting Information [Line Items]
Net sales	$ 1,184	$ 7,361		$ 2,374	$ 18,553
[1]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Geographic and Segment Inform_4

Geographic and Segment Information - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill
Goodwill, beginning	$ 899,525
Goodwill as a result of acquisition	25,893
Foreign currency adjustments	(27,348)
Goodwill, ending	898,070
Cardiopulmonary
Goodwill
Goodwill, beginning	398,245
Goodwill as a result of acquisition	0
Foreign currency adjustments	(27,348)
Goodwill, ending	370,897
Neuromodulation
Goodwill
Goodwill, beginning	398,754
Goodwill as a result of acquisition	0
Foreign currency adjustments	0
Goodwill, ending	398,754
Advanced Circulatory Support
Goodwill
Goodwill, beginning	102,526
Goodwill as a result of acquisition	25,893
Foreign currency adjustments	0
Goodwill, ending	$ 128,419

Geographic and Segment Inform_5

Geographic and Segment Information - Geographic Areas (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 143,312	$ 150,066
United States
Segment Reporting Information [Line Items]
Property, plant and equipment, net	62,704	60,852
Europe
Segment Reporting Information [Line Items]
Property, plant and equipment, net	76,309	85,313
Rest of World
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 4,299	$ 3,901

Supplemental Financial Inform_3

Supplemental Financial Information - Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 53,019	$ 43,958
Work-in-process	18,227	14,161
Finished goods	48,169	47,721
Inventory, Net	119,415	105,840
Provision for obsolescence	$ 9,000	$ 8,900

Supplemental Financial Inform_4

Supplemental Financial Information - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Operating lease liabilities	$ 10,245	$ 11,261
Contract liabilities	9,097	8,419
Amount payable to Gyrus Capital S.A.	8,767	11,418
Legal and other administrative costs	8,524	8,948
Research and development costs	6,065	5,329
Contingent consideration	5,552	11,552
Provisions for agents, returns and other	1,700	2,535
Other accrued expenses	34,002	29,475
Accrued liabilities	83,952	88,937
Contract liability	$ 11,800	$ 9,800

Supplemental Financial Inform_5

Supplemental Financial Information - Foreign Exchange (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Investment revaluation	$ 0	$ 0		$ 0	$ 4,640
Dividend Income	0	3,133		0	3,133
Foreign exchange rate fluctuations	341	1,544		3,132	1,134
Interest income	57	189		77	115
Other	(226)	1,090		(261)	1,111
Foreign exchange and other income/(expense)	1,633	239	[1]	5,537	(6,204)	[1]
Fair Value Adjustment, Derivative Liability
Debt Instrument [Line Items]
Changes in fair value (1)	0	923		0	4,090
Senior Notes | Embedded Exchange Feature Derivative Liability
Debt Instrument [Line Items]
Changes in fair value (1)	36,570	(26,048)		47,610	(52,384)
Capped Call Derivatives | Capped Call Derivative Asset
Debt Instrument [Line Items]
Changes in fair value (1)	$ (35,109)	$ 19,408		$ (45,021)	$ 31,957
[1]The condensed consolidated statements of income (loss) for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Supplemental Financial Inform_6

Supplemental Financial Information - Cash, Cash Equivalents, Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	[1]	Dec. 31, 2020	[1]
Receivables [Abstract]
Cash and cash equivalents	$ 109,022	$ 207,992
Restricted cash	297,747	0
Cash, cash equivalents and restricted cash	$ 406,769	$ 207,992	$ 329,386		$ 252,832
[1]The condensed consolidated statement of cash flows for the three and six months ended June 30, 2021 have been revised. For further details refer to “Note 1. Unaudited Condensed Consolidated Financial Statements.”

Subsequent Event (Details)

Subsequent Event (Details) - Revolving Credit Facility $ in Millions		6 Months Ended
	Jul. 06, 2022 USD ($)	Jun. 30, 2022	Aug. 13, 2021 USD ($)
Subsequent Event [Line Items]
Line of credit, maximum borrowing capacity			$ 125
Maximum
Subsequent Event [Line Items]
Debt instrument, term		364 days
Net leverage ratio			3.50
Debt Instrument, Covenant, Interest Coverage Ratio			3
Subsequent Event | Line of Credit
Subsequent Event [Line Items]
Line of credit, maximum borrowing capacity	$ 350
Debt instrument, term	5 years
Days to maturity	91 days
Discount rate	1.50%
Commitment fee percentage	0.50%
Amortization percentage, year one	2.50%
Amortization percentage, year two	5%
Amortization percentage, year three	5%
Amortization percentage, year four	7.50%
Amortization percentage, year five	10%
Subsequent Event | Line of Credit | Secured Overnight Financing Rate (SOFR)
Subsequent Event [Line Items]
Debt instrument, basis spread on variable rate	3.50%
Subsequent Event | Initial Term Facility | Line of Credit
Subsequent Event [Line Items]
Line of credit, maximum borrowing capacity	$ 300
Subsequent Event | Delayed Draw Term Facility | Line of Credit
Subsequent Event [Line Items]
Line of credit, maximum borrowing capacity	$ 50